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Abstract 
Commimity-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) 
infections have emerged as a major health concern worldwide. CA-MRSA is 
characterized by the presence of Staphylococcal Chromosomal Cassette mec (SCCmec) 
type IV and Panton-Valentine Leukocidin (pvl) gene. CA-MRSA causes infections 
ranging from skin and soft tissue infections to life-threatening conditions such as 
necrotizing pneumonia and toxic shock syndrome. Sub-inhibitory concentration of p-
lactams has been shown to affect PVL production in S. aureus in vitro. This suggests that 
PVL toxin level might be altered by different classes of antibiotics, thus influencing 
severity of disease, and should be considered in the choice of antibiotics for the treatment ‘ 
of PVL-producing staphylococcal infection. The choice of antibiotics that minimizes 
release of PVL may reduce severity of disease and improve treatment outcome in CA-
MRSA infections. 
The objectives of this study was to investigate the in vitro and in vivo effects of 
commonly used antibiotics, including ciprofloxacin, gentamicin, levofloxacin, 
vancomycin, clindamycin, fusidic acid and linezolid on pvl gene expression in CA-
4 
MRS A in Hong Kong. Novel virulence factors, phenol soluble modulins (PSMs al-4), 
have also been reported to demonstrate cytolytic activities implicated in CA-MRSA 
infections and were also examined. The in vitro study investigated the effect of 
subinhibitory concentration of antibiotics on PVL and PSMs mRNA expression at 
different growth phases, including the log phase (OD 0.6), the late log phase (OD 1.8)， 
the early stationary phase (OD 2.1) and the stationary phase (OD 2.3). A mouse 
pneumonia model was established for the in vivo study. 6-week-old female BALB/c mice 
were infected CA-MRSA intranasally and subinhibitory concentration of antibiotics was 
administered orally (for ciprofloxacin, gentamicin, levofloxacin, clindamycin，fusidic 
acid and linezolid) or intraperitoneally (for vancomycin) 2 hour after the inoculation. The 
inoculum and the harvest time were optimized at 1x10^ cfu/ml and 24 hr respectively. 
Mortality rate of mice and pneumonia score of lung were investigated. 
From the in vitro result, PVL mRNA expression was increased by all antibiotics, 
including ciprofloxacin, gentamicin, levofloxacin, vancomycin, fiisidic acid and linezolid 
but not clindamycin at different growth phases while PSMal-4 mRNA expression was 
modulated in different ways by different antibiotics. Infected mice treated with , 
ciprofloxacin, clindamycin and fusidic acid have a significantly higher mortality rate than 
the control group (without antibiotic treatment). In contrast, there was no difference in 
mortality rate for the mice administered with gentamicin, levofloxacin, vancomycin and 
linezolid compared with the control group. . 
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Taken together vancomycin, linezolid, gentamicin and levofloxacin but not ciprofloxacin, 
clindamycin and fiisidic acid appeared to produce better outcome and might be preferred 
choices in the treatment of the CA-MRSA strain prevalent in Hong Kong. The drug, 
ciprofloxacin, upregulated mRNA expression of pvl significantly and mechanisms 
influencing the regulations of these virulence factors need to be further elucidated. PVL 
may be one of the virulence factors that contribute to necrotizing pneumonia and be 
modulated by different antibiotics but other factors, such as PSMal and PSMa3 are also 












表達的影響。新硏究發現phenol soluble modulins (PSMs-al-4)亦擁有殺死中性白血 
球的能力。體外實驗探討了在細菌不同的生長期低於抑制細菌生長的不同類別的抗 
生素對PVL和PSMs的mRNA表現的影響。在動物實驗方面，6週齡雌性BALB/ c 
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Chapter 1 Introduction 
1.1 Staphylococcus aureus 
Staphylococcus aureus is one of the most prevalent pathogen isolated from hospitalized 
patients and is the most virulent species of Staphylococcus (Boyle-Vavra & Daum，2007). 
It is also an important pathogen in the community and the commonest cause of skin and 
soft tissue infections (Moran et al” 2006). It is a Gram-positive bacterium that grows in 
both aerobic and anaerobic conditions and it is grouped with Bacillus sp based on 
ribosomal RNA sequences (Kuroda et al., 2001). It forms grape-like clusters and is found 
in the nasal membranes and skin of human and animal (Kuroda et al., 2001). It is 
transmitted through direct contact (Hiramatsu, 1998). 
1.2 Methicillin-resistant Staphylococcus aureus (MRSA) 
MetMcillin-resistant Staphylococcus aureus (MRSA) is a Gram-positive coccus that is 
resistant to a group of antibiotics called beta-lactams such as penicillin and methicillin , 
(Diederen & Kluytmans, 2006). Methicillin was used in the treatment of penicillin-
resistant S. aureus in the late 1950s (Boyle-Vavra & Daum’ 2007). However, MRSA, 
that are resistant to all beta-lactams and other classes of antibiotics, soon emerged in 
healthcare environment (Boyle-Vavra & Daum, 2007). 
Over the years, MRSA has gained resistance to several classes of antibiotics, including 
fluoroquinolones, aminoglycosides, macrolides, tetracycline and lincosamide, although 
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resistance to beta-lactam is the primary resistance mechanism caused by the altered 
penicillin-binding protein (Rybak & LaPlante, 2005). Vancomycin, a glycopeptide, has 
been considered as the 'last resort' agent against MRSA infections (Rybak & LaPlante, 
2005). Unfortunately, MRSA with reduced susceptibility to glycopepetide has been found 
(Rybak & LaPlante, 2005). Vancomycin intermediately susceptible S. aureus (VISA) was 
first reported in Japan in 1997 (Hiramatsu, 1998). Since then, MRSA with reduced 
susceptibility to this drug have been reported in the United States, Europe (the UK, 
France and Spain) and the Far East (Korea and Hong Kong) (Tenover, 1999). In New 
York, Michigan and Peimsylvania, there were reports of vancomycin-resistant S. aureus 
(VRSA) (Said-Salim et al.，2003; Rybak & LaPlante，2005). 
1.2.1 Methicillin resistance of MRSA 
‘ Methicillin resistance is mediated by an altered penicillin binding protein PBP2a, which 
is a peptidoglycan transpeptidase encoded by the acquired mecA gene, conferring 
resistance to all beta-lactams. PBP2a has a low affinity to the beta-lactam antibiotics, 
including all penicillin and cephalosporin (Maltezou & Giamarellou^ 2006; Said-Salim et , 
al., 2003, Diederen & Kluytmans，2006; Boyle-Vavra & Daum，2007). There are four 
native PBPs produced by S. aureus for cell wall synthesis (penicillin-binding proteins 1， 
2，3 and 4) (Ito & Hiramatsu, 1998; Boyle-Vavra & Daum，2007). When the four native 
PBPs are bound and inactivated by beta-lactam antibiotics, PBP2a can take over the 
function of cell wall synthesis, catalyzing the formation of cross-links in bacterial cell 
wall peptidoglycan (Diederen & Kluytmans, 2006; Chambers, 1997; Boyle-Vavra & 
Damn, 2007). The mecA gene, together with its regulator genes mecl and mecR, are 
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located on the staphylococcal chromosomal cassette mec (SCCmec), a genetic element 
integrated specifically into the S. aureus chromosome (Chambers, 1997, Maltezou & 
Giamarellou, 2006; Boyle-Vavra & Daum, 2007). 
The origin of mec is not known but in Staphylococcus sciuri, a mecA homolog with 88% 
amino acid similarity to the mecA in MRSA has been found (Diederen & Kluytmans, 
2006; Chambers, 1997). Both the mecl and mecRl are located immediately upstream the 
mecA promoter and exert regulatory effect on the mecA gene transcription (Chambers, 
1997). The mecl is a DNA-binding protein that represses the mecA gene expression while 
the mecRl is the signal-transduction protein (Chambers, 1997; Hiramatsu et al.，2001). 
When the mecRl detects the presence of beta-lactams with its extracellular penicillin-
binding domain, it activates its cytoplasmic domain to make it become a protease by 
autocatalytic cleavage (Chambers, 1997; Hiramatsu et al., 2001.). It then degrades the 
mecl repressor bound on the operator of the mecA gene, leading to the expression of 
mecA gene (Chambers, 1997; Hiramatsu et al., 2001.). 
1.2.2 Staphylococcal Chromosomal Cassette mec (SCCmec) 
Besides the mecA gene, the SCCmec also contains insertion sequences and cassette 
chromosome recombinase (ccr) genes {ccrA, ccrB and ccrC) responsible for the 
integration and excision of the SCCmec and direct repeats or inverted repeats at both ends， 
acting as recognition sites of ccr genes (Diederen & Khiytmans，2006; Hiramatsu et al., 
2001; in Silco biology, 2010). Regions other than ccr and mec are called junkyard (J) 
regions {in Silco biology, 2010). There are 3 parts of the J regions: J1 (region between ccr 
• 16 
and the chromosomal region flanking SCCmec), J2 (Region between ccr and mec) and J3 
(region between mec and orJX) (Figure 1.1) (in Silco biology, 2010). When methicillin-
susceptible S. aureus (MSSA) acquires SCC/Tiec, it becomes MRSA {in Silco biology, 
2010). MRSA changes to MSSA when the SCCmec excises from the MRSA 
chromosome {in Silco biology, 2010). 
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Figure 1.1 Structure of Staphylococcal Chromosomal Cassette mec (SCCmec). Besides 
the mecA gene, the SCCmec also contains cassette chromosome recombinase (ccr) genes 
responsible for the integration and excision of the SCCmec (Diederen & Kluytm邸s, 
2006; Hiramatsu et al., 2001 ； in Silco biology, 2010). Regions other than ccr and mec are 
called junkyard (J) regions {in Silco biology, 2010). There are 3 parts of the J regions: J1 
(region between ccr and the chromosomal region flanking SCCwec), J2 (Region between 
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Figure 1.2 Conversion of MRSA and MSSA by integration and excision of SCCmec. 
When methicillin-susceptible S. aut^us (MSSA) acquires SCCmec，it becomes MRSA (m 
Silco biology, 2010). MRSA changes to MSSA when the SCCmec excises from the 
MRSA chromosome {in Silco biology, 2010). 
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Eight types of SCCmec have been identified based on the class of the mecA gene and the 
type of the ccr gene (Table 1.1) (IWG-SCC, 2009). The first three SCCmec reported were 
I to III, followed by IV to VIII (IWG-SCC, 2009). This nomenclature has been retained 
and an additional naming system has been proposed, based on the ccr type and the mec 
class (IWG-SCC, 2009). This naming system defines SCCmec type with the Roman 
numerals in the order in which they are reported, followed by the ccr and mec genes 
(IWG-SCC, 2009). For example, SCCmec type I (IB) indicates SCCmec containing type 
1 ccr and class B mec (IWG-SCC, 2009). 
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Table 1.1 Staphylococcal Chromosomal Cassette mec {SCCmec) types (IWG-SCC, 
2009). 
SCCmec type ccr gene complex mec gene complex 
I 1 (AlBl) B 
II 2 (A2B2) A 
III 3 (A3B3) A 
IV 2 (A2B2) B 
V 5 (C) C2 
VI 4 (A4B4) B 
VII 5 (C) CI 
VIII 4 (A4B4) A 
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SCCmec type I contains only the mecA gene as the sole resistance gene, whereas 
SCCmec types II and III contain multiple resistance genes for non-beta-lactam antibiotics 
and confer to the multidrug resistance commonly found in hospital-associated MRSA 
(HA-MRSA) isolates (Diederen & Kluytmans，2006). Strains of community-associated 
MRSA mostly harbored the SCCmec type IV or V and they are typically susceptible to 
multiple antibiotics since there are usually no other antibiotic resistance genes on the 
SCCwec (Diederen & Kluytmans, 2006). The size of the five SCCmec complexes varies, 
ranging from �30kb to 60kb or greater (Ito & Hiramatsu，1998). Given that the size of the 
MRSA genome is �3000kb，the size of the SCCmec is very large as it consists of �1-2% 
of the entire genome (Ito & Hiramatsu, 1998). 
1.2.3 Hospital-associated MRSA (HA-MRSA) and Community-
associated MRSA (CA-MRSA) 
MRSA can be categorized into hospital-associated MRSA (HA-MRSA) and community-
associated MRSA (CA-MRSA) (Rybak & LaPlante，2005). The Centers for Disease 
Control and Prevention (CDC) has established criteria to differentiate CA-MRSA from , 
HA-MRSA infections. According to these criteria, community-associated MRSA 
infection (CA-MRSA) is defined by an MRSA infection in a patient who lacks typical 
risk factors for hospital-associated infection, including the diagnosis of MRSA by a 
positive MRSA culture within 48 hours after patient admission to the hospital; no 
medical history of infection with MRSA, hospitalization, dialysis, admission to a nursing 
home and surgery; and no permanent medical devices or indwelling catheters passing 
through the skin into the body (CDC, 2010). 
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1.2.3.1 Hospital-associated MRSA (HA-MRSA) 
HA-MRSA typically carries larger SCCmec types I，II or III，which includes additional 
antibiotics resistance genes but CA-MRSA carries smaller SCCmec type IV or SCCmec 
type V (Boyle-Vavra & Daum，2007; Maltezou & Giamarellou^ 2006). The larger size of 
SCCmec types I-III is due to the presence of additional non-beta-lactam antibiotic 
resistance genes, which are usually not found in SCCmec types IV and V (Boyle-Vavra 
& Daum, 2007; Maltezou & Giamarellou^ 2006). Therefore, CA-MRSA is often resistant 
only to beta-lactams whereas HA-MRSA, in contrast, is usually resistant to multiple 
antibiotics (Diederen & Kluytmans, 2006). 
1.2.3.2 Community-associated MRSA (CA-MRSA) 
CA-MRSA is usually pan-susceptible to non-beta-lactam antibiotics, while HA-MRSA is 
typically resistant to multiple antimicrobials (Boyle-Vavra & Daum, 2007; Rybak & 
LaPlante, 2005). CA-MRSA is characterized by the presence of SCCmec type IV and pvl 
gene (Maltezou & Giamarellou, 2006). However，multidrug resistance CA-MRSA has 
also been reported (Diep et al., 2006). For example, a multidrug resistant CA-MRSA 
strain USA300 has been found acquiring mobile genetic elements encoding for multidrug 
resistance and virulence determinants (Diep et al., 2006). ‘ In a survey of 117 CA-MRSA 
isolates collected from the United States, Australia, Switzerland，France, New Zealand 
and Western Samoa, all of them carried the SCCmec type IV and the PVL gene 
(Vandenesch et a l , 2003). 
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CA-MRSA can cause diseases varying from mild infection, such as skin and soft tissue 
infections to life-threatening infections such as necrotizing pneumonia and toxic shock 
syndrome (Boyle-Vavra & Daum，2007). Skin infections caused by CA-MRSA can 
rapidly progress to severe necrotizing pneumonia due to its high virulence capability 
(Rybak & LaPlante，2005). 
Another genetic difference between CA-MRSA and HA-MRSA is the presence of an 
integrated bacteriophage (0SLT), carrying the pvl gene in CA-MRSA but not in HA-
MRSA (Boyle-Vavra & Daum，2007). The pvl gene is widely associated with the 
SCCmec types IVandV but not SCC/wec types I，II or III (Boyle-Vavra & Daum，2007). 
Therefore, pvl is common in CA-MRSA but rarely present in HA-MRSA (Diederen & 
Kluytmans, 2006). Figure 1.3 shows the origin of CA-MRSA. 
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# 二 二 0 CA-MRSA 
MSSA r：^/^ chromosome pvl gene 
o - o - b ^ p 
Phage ^ ^ SCCmec IV 
Chromosome carrying pvl 
gene infects SCCmec IV 
MSSA Horizontal transfer of 
SCCmec IV from 
coagulase-negative 
staphylococci 
Figure 1.3 The origin of CA-MRSA. A MSSA strain was first infected by the phage 
0SLT, which carried the pvl gene Boyle-Vavra and Daum 2007). The mecA gene was 
then horizontally transferred to this MSSA strain and CA-MRSA producing PVL 
.. emerged (Boyle-Vavra and Daum 2007). 
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It was proposed that CA-MRSA resulted from the horizontal transfer of SCCmec type IV 
from coagulase-negative staphylococci to MSSA (Deresinski, 2005; Boyle-Vavra & 
Daum, 2007). It is because SCCmec IV was first found in a commensal Staphylococcus 
epidermidis in the 1970s，which is earlier than the discovery of SCCmec IV in S. aureus, 
which was in the 1980s (Boyle-Vavra & Daum, 2007). Also, in a study of 44 metMcillin-
resistant Staphylococcus epidermidis isolates obtained from the blood of prosthetic valve 
endocarditis patients during 1973-1983, 36% bore SCCmec type IV (Deresinski, 2005). 
People therefore suggested that that SCCmec IV was transferred from the putative donor 
S. epidermidis into community adapted MSSA strains sometime in the 1980s and created 
CA-MRSA (Deresinski, 2005; Boyle-Vavra & Daum，2007). 
One of the alarming reports of deaths due to CA-MRSA infections was from the late 
1990s, when four pediatric deaths caused by CA-MRSA in North Dakota and Minnesota 
of the United States were reported (CDC MMWR, 1999). Since，many more cases of CA-
MRSA infections have been reported around the world (Otto, 2010). Despite being 
named as community-associated MRSA strains, they are not restricted to the community 
since they have been associated with nosocomial infections as well (Diederen & ‘ 
Kluytmans, 2006). The successful widespread of CA-MRSA may be the result of greater 
efficiency of transfer of the SCCmec type IV, which is smaller in size (due to the lack of 
other resistance genes beside mecA) compared with SCCmec types I-III and also impose 
a less fitness cost to the recipient clone (Diederen & Kluytmans，2006; Diep & Otto, 
2008). CA-MRSA carrying SCCmec type IV has been demonstrated to replicate more 
rapidly than HA-MRSA carrying SCCmec types I-III (Diederen & Kluytmans, 2006). 
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This relatively greater fitness of CA-MRSA strains may be the reason of its success in 
displacing HA-MRSA strains in some hospitals after being introduced from the 
community (Diederen & Kluytmans，2006). 
Recently，there have been increasing reports of CA-MRSA in the commimity and CA-
MRSA is displacing HA-MRSA at some hospitals (Diederen & Kluytmans, 2006). For 
example, in San Francisco, it was found that there was a progressive replacement of type 
II SCCmec MRSA with the type IV SCCmec CA-MRSA and this coincided with the 
dramatic increase (>4 fold) in community methicillin resistance in that city between 1998 
and 2002 (Carleton et al., 2004). 
Compared with HA-MRSA, it was observed that the doubling time of CA-MRSA is 
shorter, that is, CA-MRSA has a faster growth rate (Rybak & LaPlante, 2005). This high 
growth rate may be beneficial to outcompete other bacteria, including the normal flora, 
and result in successful colonization (Rybak & LaPlante, 2005). 
1.2.4 Pathogenesis of MRSA infection 
S. aureus is a natural commensal found in humans while it can become a pathogen 
(Gordon & Lowy, 2008). Approximately 30% individuals are intermittently nasally 
colonized with S. aureus and 20% are persistently colonized (Gordon & Lowy, 2008). 
The risk of infection is increased for people colonized with S. aureus as the bacteria can 
be introduced once the host defenses are breached, for examples, patients with 
immunodeficiency syndrome or undergoing surgery or dialysis are at high risk (Lowy, 
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1998; Gordon & Lowy，2008). Transmission of S. aureus is through the contact with 
colonized individuals (Lowy, 1998). 
The pathogenesis of MRSA involves three steps, adherence to cell surface, penetration of 
the host physical barrier and evasion of the host inunune system (Gordon & Lowy，2008). 
Adherence to host tissue can be mediated by many cell surface proteins on S. aureus and 
they are collectively called microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) (Gordon & Lowy，2008). MSCRAMMs can bind to various 
molecules of the host tissue such as collagen and fibrinogen and different MSCRAMMs 
may target on the same host molecule (Gordon & Lowy，2008). For an example, teichoic 
acid is responsible for attachment on the nasal mucosa of the host (Iwatsuki et al., 2006). 
Several virulence factors are involved in the penetration into the host tissue, including 
proteases and hyaluronidase for tissue destruction and hence facilitating the spread of the 
bacteria into the tissue (Lowy, 1998; Gordon & Lowy，2008). S. aureus may also produce 
lipase that allows the bacteria to persist in the fatty secretion of the skin (Otto, 2004). 
Exfoliative toxins secreted by the bacteria allow them to spread within the epithelium by , 
disruption cell-cell cohesion and may lead to staphylococcal scalded skin syndrome 
(SSSS) (Iwatsuki et al., 2006; Dissemond，2009). 
After invasion, S. aureus may produce virulence factors to help in evading the host 
defense (Gordon & Lowy, 2008). For examples, the bacteria may express coagulase and 
clumping factor A on the cell wall to prevent recognition by phagocytes (Dissemond, 
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2009). S. aureus may also produce protein A on its capsule, which binds to the Fc region 
of antibodies and prevents opsonization and phagocytosis (Dissemond, 2009). Moreover, 
S. aureus may secrete heat-resistant enterotoxins, which are superantigen that causes 
extensive proliferation of non-specific T-cell by binding to the MHC class II molecule 
and cytokine release (Lowy, 1998; Dissemond, 2009). This decreases the specificity of 
the adaptive immune system against the bacteria and may lead to toxic shock syndrome 
and food poisoning (Lowy, 1998 & Dissemond，2009). 
MRSA can cause diseases varying from mild infection such as skin and soft tissue 
infections to life-threatening infections, such as necrotizing pneumonia (Boyle-Vavra & 
Daum, 2007). Nosocomial pneumonia caused by MRSA contributes to the morbidity and 
mortality of hospitalized patients (Niederaian, 2009). The bacteria accounted for 17 % 
nosocomial pneumonia in the National Nosocomial Infections Surveillance in the United 
State (Niederman, 2009). Before 1950, pneumonia caused by staphylococci was rare and 
the mortality rate was low (<3%) with appropriate antibiotic therapy (Morgan, 2007). 
However, since 1999，necrotizing pneumonia caused by Panton-Valentine leukocidin 
(PVL)-producing strains of S. aureus, have been associated with a high mortality rate of ‘ 
75% (Morgan, 2007). 
1.2.4.1 Possible virulence genes contributing to necrotizing pneumonia 
1.2.4.1.1 Panton-Valentine Leukocidin (PVL) 
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Panton-Valentine Leukocidin (PVL) was first identified as "substance leukocidine" by 
Van deVelde in 1894 because of its ability of leukocytes lysis (Panton et al.，1932). PVL 
is a bicomponent, pore-forming leukotoxin that targets cells of the immune system e.g. 
polymorphonuclear neutrophils (PMN) (Rybak & LaPlante，2005; Lina et al., 1999). PVL 
was suggested to be the major virulent factor of necrotizing pneumonia (Tristan et al., 
2007). Severe sepsis associated with necrotizing pneumonia can cause death within 24-48 
hours of hospitalization (Boyle-Vavra & Daum，2007). 
The active form of PVL requires the assembly of two polypeptides, LukS-PV and LukF-
PV, which are encoded by two contiguous and cotranscribed genes {lukS-PVdead lukF-PV) 
(Tristan et al., 2007). The LukS-PV and LukF-PV subunits of the PVL toxin are secreted 
from the MRSA which then assemble into a heptamer and form a pore on PMN 
membrane (Boyle-Vavra 8c Daum，2007). This results in PMN lysis and thus the release 
’ of inflammatory mediators such as IL-8 and histamine from the lysed cell, initiating an 
inflammatory response and tissue necrosis (Boyle-Vavra & Daum，2007; Tristan et al., 
2007). 
« 
It was shown that purified PVL has no effect on epithelial cells and this suggested that 
PVL is not directly responsible for tissue necrosis (Boyle-Vavra & Daum, 2007). This 
PMN lysis is mediated by PVL causes the evasion of the first line of the host defense 
against bacterial infection and excessive neutrophil cell death may define the first step of 
pathogenesis of community-associated methicillin-resistant Staphylococcus aureus (CA-
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MRSA) and promote disease development (Boyle-Vavra & Daum，2007; Loffler et al., 
2010). 
The role of PVL in necrotizing pneumonia is still being debated since conflicting data 
have been obtained from several studies. In a study conducted by Labandeira-Rey et al. 
(2007), PVL was suggested as the major virulent factor that contributed to necrotizing 
pneumonia using a mouse model (Labandeira-Rey et al., 2007). In this study mice were 
infected with PVL-positive and PVL-negative strains (Labandeira-Rey et al., 2007). Lung 
sections revealed that there were bronchial epithelial damage, hemorrhage and 
recruitment of neutrophils when the lungs were infected with the PVL-positive strains 
while normal lung structures were observed when the lungs were infected with the PVL-
negative strains (Labandeira-Rey et al, 2007). Mice were infected with the PVL-negative 
strains that have been complemented with a PVL encoding plasmid (Labandeira-Rey et 
‘ al., 2007). The results were that there was massive lung tissue damage and the mortality 
rate was 35-80% within 24 hours after inoculation (Labandeira-Rey et al., 2007). Lung 
sections were stained with antibodies against LukS-PV and PVL toxin was detected 
(Labandeira-Rey et al., 2007). The association between PVL and necrotizing pneumonia , 
had also been seen in clinical cases, for example, in U.K., an 80-year-old female patient 
with no history of recent hospitalization had a severe community acquired pneumonia 
caused by pvl- positive CA-MRSA, which was resistant to penicillin but sensitive to 
multiple antibiotics such as vancomycin, gentamicin, tetracycline, ftisidic acid and 
rifampicin (Turtle et al., 2009). 
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A recent study done by Diep et al. (2010) suggested that PVL mediated necrotizing 
pneumonia (Diep et al., 2010). They developed a rabbit model of necrotizing pneumonia 
and study the effect of PVL on necrotizing pneumonia using the wild-type CA-MRSA 
USA300 and the isogenic PVL-deleted strain and PVL-complemented strain (Diep et al., 
2010). They found that PVL enhanced the CA-MRSA USA300 virulence to cause 
necrotizing pneumonia (Diep et al.，2010). A more extensive necrosis, disruption of 
alveoli architecture and PMN infiltration were observed in the wild-type strain compared 
with the PVL-deleted strain (Diep et al., 2010). 
On the other hand, one study demonstrated that PVL can only cause rapid apoptosis in 
human and rabbit neutrophils, but failed in murine and monkey neutrophils (Loffler et al., 
2010). On the contrary, a newly identified cytolytic protein, called phenol-soluble 
modulins (PSMs), did not have this species-specificity and efficiently lysed neutrophils 
“ of different species (Loffler et al., 2010). In another study, the authors failed to 
demonstrate the differences in virulence of PVL-positive and PVL-negative CA-MRSA 
using a mouse model (Voyich et al., 2006). Isogenic PVL knockout strains were found to 
be as virulent as the respective PVL-positive wild-type strains in abscesses size and , 
human neutrophil lysis and thus they concluded PVL was not the major virulent 
determinant in CA-MRSA (Voyich et al., 2006). Wardenburg et al. (2007 & 2008) 
carried out similar approaches comparing the wild-type and isogenic ；7v/-knockout strain 
in murine models and they also concluded PVL was not a contributor to pneumonia since 
histological results indicated there were no difference in overall mortality and pneumonia 
grading (in terms of infiltration of immune cell, alveolar architecture, hemorrhage and 
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bacterial infiltrates) between the wild-type PVL-positive CA-MRSA strains and their 
respective pvl deleted strains (Wardenburg et al., 2007 & 2008). Table 1.2 summarizes 
the effect of PVL on necrotizing pneumonia using an animal pneumonia model. 
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Table 1.2 Effect of PVL on necrotizing pneumonia done by different researcher 
group using animal pneumonia model 
Researcher Labandeira-Rey et Diep et al 2010 Voyich et al Wardenburg et al 
Group al 2007 2006 2007 and 2008 
Experiment Mice were PVL enhanced Isogenic PVL There were no 
done for infected with the CA-MRSA knockout difference in 
investigation PVL-positive and USA300 strains were overall mortality 
of effect of PVL-negative virulence to found to be as and pneumonia 
PVL on strains and PVL- cause virulent as the grading (in terms 
necrotizing negative strain necrotizing respective of infiltration of 
pneumonia complemented pneumonia. A PVL-positive immune cell, 
using animal with PVL more extensive wild-type alveolar 
model encoding plasmid. necrosis, strains in architecture. 
Pneumonia disruption of abscesses size hemorrhage and 
observed in PVL- alveoli and human bacterial 
positive strains architecture neutrophil lysis infiltrates) 
but not in PVL- and PMN between the 
negative one infiltration wild-type PVL-
were observed positive CA-
in the wild-type MRSA strains 
strain and their 
compared with respective pvl 
the PVL- deleted strains 
,, deleted strain 





pneumonia | _ 
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Necrotizing pneumonia is often associated with PVL-producing S. aureus and its lethality 
rate is high (30-80%) (Gillet et al., 2002). Pneumonia caused by PVL-positive S. aureus, 
compared to the PVL-negative S. aureus, is often preceded by influenza-like symptoms 
(Gillet et al., 2002). It was found that PVL-positive S. aureus has a higher affinity of 
binding to damaged human airway epithelium basement membrane type I and IV 
collagens and laminin than PVL-negative S. aureus (de Bentzmann et al., 2004). In the 
same study it was also shown that recombinant PVL had no effect (no cytotoxicity or 
alteration of cell confluency) on a human bronchial cell line (de Bentzmann et al., 2004). 
However, when crude supernatant obtained from the PVL-positive S. aureus and PVL-
negative S, aureus culture was applied to the human bronchial cell line, an altered cell to 
cell contact in confluent layers was observed (de Bentzmann et al., 2004). This suggests 
that other exoproteins but not PVL may be responsible for epithelial damage (de 
Bentzmann et al., 2004). 
Since expression of most S. aureus exoproteins including PVL is controlled by the 
accessory gene regulator) agr quorum-sensing system, which will be upregulated by this 
system at high cell density, de Bentzmannn et al., hypothesized that in necrotizing . 
pneumonia, a high number of PVL-positive S. aureus adhere to damaged airway 
epithelium due to the high affinity of the PVL-positive S. aureus to the type I and IV 
collagens and laminin, which in turn trigger the agr quorum-sensing mechanism and 
thereby inducing PVL production and causing necrotizing pneumonia (de Bentzmann et 
al.，2004). 
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1.2.4.1.2 Phenol-soluble modulins (PSMs) 
Phenol-soluble modulins (PSMs) are novel virulence factors identified in Staphylococcus 
aureus, which have the ability to lyse human neutrophils, just like the cytolytic activity of 
PVL (Wang et al” 2007; Joo et al., 2010). PSMs have been found to have the ability to 
promote skin infection caused by CA-MRSA and they are produced by most S. aureus 
strains and S. epidermidis, where they are reported to have a role in eliciting an 
inflammatory response, for example, activate NF-KB and stimulate cytokine production 
such as TNF-a and IL-6. (Liles et al.: 2001; Wang et al.，2007; Joo et al., 2010). Although 
PSMs are produced by most S. aureus isolates, their production was found to be much 
higher in vitro in CA-MRSA than in HA-MRSA and so it is proposed that PSMs 
contribute to the enhanced virulence of CA-MRSA (Wang et al , 2007). In S. aureus, 
PSMs includes the four shorter (-20 amino acids) peptides called the PSMa peptides 
(PSMal，PSMa2, PSMa3 and PSMa4), the two longer ( � 4 0 amino acids) peptides called 
the PSMp peptides (PSMpi and PSMp2) and the 5-toxin (Mehlin et al., 1999; Wang et al., 
2007; Joo et al., 2010). The PSMa and PSMp peptides and the 5-toxin are encoded in the 
psma and psmfi operons and within the region coding for RNAIII (an effector molecule 
of the agr gene) respectively (Wang et al , 2007; Joo et al , 2010). PSMa shows strong , 
cytolytic activity while 6-toxin has moderate effect in neutrophil' lysis (Otto, 2010). 
PSMP lacks the cytolytic activity (Otto, 2010). 
1.3 Evolution of MRSA 
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Methicillin was a semisynthetic derivative of penicillin, which is chemically modified to 
prevent the degradative action of penicillinase (Diederen & Kluytmans, 2006). The drug 
was used as a therapeutic agent in Europe in 1959-1960. (Diederen & Kluytmans，2006). 
The first methicillin-resistant S. aureus (MRSA) strain was isolated in England only 1 
year after the introduction of methicillin, followed by the first MRSA outbreak in 1963 
(Jevons, 1961; Stewart & Holt，1963). This MRSA strain, carrying SCCmec type I，is 
now known as the Archaic clone and disseminated throughout the world in the following 
years, first to European countries followed by Australia, Japan and the USA (Deurenberg 
& Stobberingh, 2008; Enright et al., 2002). Since then, MRSA has become the most 
prevalent pathogen causing hospital infection worldwide and cases of MRSA infections 
were still increasing in many countries (Diederen & Kluytmans，2006). 
The relation between the first MRSA clone and subsequent various MRSA and MSSA 
’ clones was described in the multi-clone theory as supported by the study in which 359 
MRSA and 553 MSSA strains isolated in 20 countries between 1961 and 1999 were 
investigated (Deurenberg & Stobberingh, 2008). 
It was found that ST8-MSSA is the putative ancestor of the first MRSA strain (ST250-
MRSA-I) since there was only one point mutation in the yqiL locus between ST8 and 
ST250 (Deurenberg & Stobberingh，2008). Over time, the ST8-MSSA acquired SCCmec 
type I，II and IV and became different MRSA clones (Deurenberg & Stobberingh, 2008). 
Current MRSA strains were either descendants of the preexisting clones or being created 
by the acquisition of mec gene in MSSA (Rybak & LaPlante，2005). Analysis on the 
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emergence of VISA and VRSA isolates in recent years revealed that these isolates have 
emerged from ST5-MRSA-II (Enright, 2003). 
1.4 Epidemiology of MRSA 
1.4.1 Epidemiology of MRSA worldwide 
The prevalence of MRSA infection varies widely between countries although MRSA has 
spread worldwide (Diederen & Kluytmans，2006). It is consistently higher in the United 
States, Japan and Southern Europe (more than 40% of S, aureus infections are MRSA) 
than Northern Europe (less than 2% in Scandinavia, The Netherlands and Switzerland) 
(Diederen & Kluytmans, 2006). 
1.4.1.1 Epidemiology of HA-MRSA worldwide 
In the 1980s, five major MRSA clonal lineages have been defined, namely the Brazilian 
clone，Hungarian clone, Iberian clone, New York/Japan clone and Paediatric clone, 
which have disseminated worldwide (Oliveira et al., 2002). The Brazilian clone was first ‘ 
reported in Brazil in 1992 and then was found in Uruguay, Argentina, Chile, Portugal and 
the Czech Republic (Oliveira et al., 2002). The Hungarian clone was first isolated in 
hospitals in that country and spread to Australia, Canada, China and Taiwan (Oliveira et 
al, 2002; Deurenberg & Stobberingh，2008). The Iberian clone was first found in Spain 
in 1989 and since then there were reports of this clone in France, Italy, the UK, Belgium, 
Portugal, Germany, Switzerland, Poland, Czech Republic, Sweden and the USA (Oliveira 
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et al., 2002; Deurenberg & Stobberingh, 2008). The New York/Japan clone was reported 
in Japan, the USA, Finland, Belgium, Korea, Mexico, France and Germany (Deurenberg 
& Stobberingh，2008) and the Paediatric clone was first reported in Portugal in 1992 and 
then in Poland, the USA, Colombia, Denmark and Turkey (Oliveira et al., 2002; 
Deurenberg & Stobberingh, 2008). 
1.4.1.2 Epidemiology of CA-MRSA worldwide 
The vast majority of CA-MRSA infections worldwide are mediated by five predominant 
CA-MRSA clones, namely the Midwest clone, the Southwest Pacific/Oceania clone, the 
European clone, the Pacific clone and the pandemic clone USA3 00 (Diep & Otto, 2008). 
The Midwest clone belongs to the sequence type STl clonal lineage and was found in 
USA, Europe, Asia and Australia (Diep & Otto，2008; Deurenberg & Stobberingh，2008). 
The Southwest Pacific/Oceania clone, which is known as the ST30 clonal lineage, were 
found in outbreaks in Greece, Mexico, Australia，South America and the USA (Diep & 
Otto, 2008; Deurenberg & Stobberingh, 2008). The iEuropean clone belongs to the ST80 
clonal linage and caused endemic disease in Europe and Middle-East while the Pacific 
clone belongs to the ST59 clonal lineage and was reported in Taiwan, Vietnam and the 
USA (Diep & Otto，2008; Deurenberg & Stobberingh, 2008). The USA300 clone, 
belonging to ST8 clonal lineage, is now pandemic in USA, Canada and European 
countries (Diep & Otto，2008). It was observed that when this clone is introduced into a 
new geographic area, it displaced the locally endemic CA-MRSA strains belonging to the 
STl, ST30, ST59 and ST80 clonal lineage (Diep & Otto，2008). 
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1.4.2 Epidemiology of MRSA in Hong Kong 
HA-MRSA first appeared in the 1960s in Hong Kong and hospitals were endemic for 
HA-MRSA in 1980s (Hospital Authority Central Committee on Infectious Diseases and 
Infection Control Branch, Center for Health Protection, 2006). In a longitudinal study of 
MRSA rates in a teaching hospital in Hong Kong, there were 5707 patient episodes of 
new MRSA isolation among 1203175 deaths and discharges (D&D) during this 12-year 
period from 1989 to 2000 (Ip et al., 2004). The overall incidence rate of MRSA isolation 
was 0.47/100 D&D (Ip et al , 2004). The incidence was 0.81/100 D&D in 1989, which 
decreased to 0.33/100 D&D in 1995, followed by a rise to 0.50/100 D&D in 2000 (Ip et 
al , 2004). In 1998-1999, MRSA isolates accounted for 69.8% of the total S. aureus 
isolates of hospitalized patients in Hong Kong and this rate was the highest compared 
�� with all Asia-Pacific areas studied, including Japan, Taiwan and Singapore (Bell et al.， 
2002). 
CA-MRSA was first reported in Hong Kong in 2004 (Tsang & Tsui，2007; Ho et al” 
2004). During the period January 1，2005-June 30, 2007, there were generally increasing 
reported cases of CA-MRSA (Tsang & Tsui，2007). In a study between January 1 and 
June 30, 2007, 70 cases of CA-MRSA infections were reported and it was found that 
those cases were more or less evenly distributed among different districts (Tsang & Tsui, 
2007). According to a study conducted by Ho et al., among 298 patients with skin and 
soft tissue infections (recruited from November 2006 to February 2007)，10.4% of all S. 
aureus isolates and 5% of all abscesses were mediated by pvl-positive CA-MRSA (Ho et 
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al., 2008). It also pointed out that Filipino ethnicity was significantly more likely than 
Chinese to be infected by pvl-positive CA-MRSA (Ho et al., 2008). Since most of the 
Filipinos in Hong Kong are domestic workers, this association was postulated to be due 
to poverty and inadequate access to medical service (Ho et al., 2008). 
The major nosocomial MRSA strains spreading in Hong Kong hospitals belonged to ST239 
and carried SCCmec type III (Ho et al., 2007; Ip et al., 2003; Ip et al., 2005). For CA-MRSA, 
the major lineages were ST30-rV, ST59-V and STSO-IV (Ho et al., 2009). These strains 
were believed to have been introduced from other countries via international travel since 
there were over lO-million visitors coining to Hong Kong every year (Ho et al., 2009). The 
ST59 strain might be related to mainland China since all isolates of ST59 were recovered 
from individuals living close to the border with China or having a history of frequent cross-
border travel between China and Hong Kong (Ho et al., 2009). 
1.5 Clinical significance of MRSA 
Treatment of serious S. aureus infections is still a challenging problem today although , 
highly active antimicrobial agents are available (Diederen & Kluytmans，2006). MRSA 
infections are associated with increased morbidity, mortality and length of hospital stay 
of patients and thus lead to a major burden on healthcare services (Diederen & 
Kluytmans, 2006). In some hospitals, MRSA infection rate can be as high as 50% of all 
nosocomial infections (Said-Salim et al., 2003). 
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In the USA, MRSA is now a leading cause of death by any single infectious agent 
(Klevens et al.，2007). In 2007，a high incidence of invasive MRSA disease of 
31.8/100,000 population has been reported, and was associated with 20% mortality 
(Klevens et al., 2007). S. aureus is the major cause of ventilator-associated pneumonia 
(VAP) in US hospitals and in Europe (Shorr et al., 2006). The report showed that for 
bacteremia and surgical site infections, MRSA significantly increased length of stay 
(LOS) and hospital charges compared with MSSA, with an excess LOS of 2-8 days and 
charges of US $ 7000-14000 (Shorr et al, 2006). 
It has been well established that Staphylococcus aureus can establish secondary bacterial 
pneumonia post-influenza illness and this complication contributes to the morbidity and 
mortality of the patients during influenza pandemics (El Ahmer et al., 1999; Murray et al., 
2010). This secondary infection of CA-MRSA is due to the increased susceptibility 
� caused by the influenza vims and results in post-influenza staphylococcal pneumonia in 
immunocompetent individuals (Cheng et al., 2009; Hageman et al., 2006). It has been 
shown that human respiratory epithelial cell lines infected with influenza virus increases 
the binding of S. aureus (El Ahmer et al., 1999). , 
CA-MRSA was associated with co-infections in the recent swine HlNl influenza 
pandemic in 2009 (Murray et al., 2010). Likewise, in Hong Kong, the first case of death 
due to S-OIV infection complicated by bacterial pneumonia caused by CA-MRSA in an 
immunocompetent adult had been reported (Cheng et al, 2009). In this patient MRSA 
isolate was found in both blood and pleural fluid cultures and this isolate was sensitive to 
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vancomycin, clindamycin, erythromycin, fusidic acid, gentamycin and cotrimoxazole 
(Cheng et al., 2009). It carried SCCmec type IV and pvl gene and belonged to ST30 
(Cheng et al, 2009). 
1.6 Antibiotics 
According to the guidelines for the treatment of HA-MRSA infections in the UK，early 
use of vancomycin is the drug of choice for treatment of HA-MRSA infection when the 
patients were reported to be culture positive for MRSA (Gemmell et al.，2006). Linezolid 
or glycopeptides were suggested for the treatment of bacteraemia and skin and soft tissue 
infection caused by HA-MRSA (Gemmell et al, 2006). Rifampicin and fusidic acid can 
be used in the treatment of HA-MRSA infection in the UK where the resistance rate to 
these drugs were still rare (Gemmell et al., 2006). However, in area where these agents 
, were widely used, such as Australia, the rifampicin resistance rate was 30-60% and 
treatment with rifampicin may not be useful (Gemmell et al., 2006). Rifampicin and 
fusidic acid should not be used alone and they are usually given in combination 
(Gemmell et al., 2006). Clindamycin can be considered as a drug of choice for treatment , 
of erythromycin-susceptible MRSA (Gemmell et al, 2006). For the treatment of CA-
MRSA infections, vancomycin, daptomycin, linezolid or clindamycin can be the drugs of 
choice (Marisel, 2009). 
1.6.1 Beta-lactams 
Beta-lactams include penicillins, cephalosporins, carbapenems and other related 
compounds that contain the beta-lactam ring in their structures (Holten & Onusko，2000). 
‘ 43 
They are used in the treatment of Gram-positive, Gram-negative and anaerobic pathogens 
and exert their effect by interfering the crosslinking of the peptidoglycans in the bacterial 
cell wall (Holten & Onusko, 2000). However, resistance mechanism against beta-lactams 
has been developed in MRSA, as described in section 1.2. 
Ceftobiprole is the first agent belonging to the fifth generation of cephalosporins and this 
agent has the ability against MRSA (Bosso, 2005; Kosowska et al., 2005). The activity of 
ceftobiprole against MRSA is due to its ability of binding normal PBPs and PBP2a at a 
very high affinity (Kosowska et al., 2005). Unlike the older first to fourth, generation of 
cephalosporins, in which drug resistance has been developed since they do not bind 
PBP2a, the antibacterial activity of ceftobiprole against MRSA, which shows a strong 
inhibition effect on PBP2a, makes this drug being effective against MRSA (Hebeisen et 
al., 2001). Another novel cephalosporin, ceftaroline, has also been proven to be bioactive 
in the antibacterial activity against MRSA in vitro and in vivo (Talbot et al., 2007). It is 
very active against VISA and methicillin-resistant coagulase-negative staphylococci 
(Talbot et al., 2007). Its anti-MRSA activity is also attributed to the high affinity of 
binding of PBP2a (Talbot et al., 2007). ‘ 
1.6.2 Fluoroquinolone 
Ciprofloxacin and levofloxacin are antibiotics belonging to the fluoroquinolone drug 
class (Madurga et al., 2008). They have a broad-spectrum bactericidal activity against 
both Gram-positive and Gram-negative bacteria (Madurga et al., 2008). They function 
by inhibiting the two essential bacterial enzymes called DNA gyrase and DNA 
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topoisomerase IV (Drlica & Zhao, 1997). DNA gyrase is responsible for the supercoiling 
of DNA, while topoisomerase IV controls the unwinding and winding of DNA for 
transcription and DNA replication (Drlica & Zhao, 1997). Therefore, inhibiting these two 
enzymes means that cell growth and division is inhibited, leading to the bactericidal 
effect (Drlica & Zhao, 1997). However, it is observed that treatment of MRSA infection 
with fluoroquinolones is correlated with the rapid development of resistance to this drug 
(Rybak & LaPlante，2005) 
1.6.3 Linezolid 
Linezolid is the first drug of the antimicrobial class, oxazolidinones approved for clinical 
use (Moellering, 2003). It is a totally synthetic compound and so there are no naturally 
occurring resistance mechanisms in bacteria (Moellering, 2003). It is effective against all 
, clinically important Gram-positive bacteria, including MRSA, penicillin-resistant 
pneumococci and vancomycin-resistant enterococci and it has good penetration into skin 
and soft tissue infections (Moellering, 2003; Rybak & LaPlante, 2005). Linezolid is an 
inhibitor of bacterial protein synthesis and thus stopping the growth and reproduction of 
bacteria (Moellering, 2003). Linezolid targets on the first step, initiation, of the protein 
synthesis by binding to the 23 S ribosomal RNA of the 5OS subunit such that the 
formation of the 70S initiation complex (including the tRNA, mRNA and the 3OS and 
50S ribosomal subunits) for translation is interfered (Moellering，2003). 
1.6.4 Glycopeptides 
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Vancomycin is a glycopeptide antibiotic which was first isolated from Streptomyces 
orientalis in 1956. It was widely used in 1958, when penicillinase-producing 
staphylococci were emerging and it fell into disuse 2 years later due to the advent of 
methicillin (Nailor & Sobel，2009). Vancomycin is widely used for the treatment of 
serious Gram-positive bacterial infections, including MRSA (Nailor & Sobel，2009). It 
exhibits bactericidal activity by the inhibition of cell wall synthesis of bacteria (Nailor & 
Sobel, 2009). It does so by irreversibly binding to the terminal D-alanyl-D-alanine of the 
bacterial cell wall precursors and inhibiting peptidoglycan polymerase and 
transpeptidation reactions (Appelbaum, 2006; Nailor & Sobel, 2009). This inhibits the 
cross-linking of peptidoglycan of the cell wall (Nailor & Sobel，2009). 
1.6.5 Aminoglycosides 
., Gentamicin belongs to a group of antibiotics called aminoglycoside antibiotics (Leggett, 
1990). It is active against Gram-negative bacteria and Gram-positive staphylococci 
(Leggett, 1990). Its mode of action is the inhibition of protein synthesis by binding to the 
30S subunit of the bacterial ribosomes (Leggett, 1990). 
1.6.6 Fusidic acid 
Fusidic acid is first isolated from the fungus Fusidium coccineum in monkey faeces 
(Collignon & Tumidge，1999). It has a narrow spectrum of action mainly against 
staphylococci and a variety of other Gram-positive bacteria, but against only a limited 
number of Gram-negative bacteria (Collignon & Tumidge，1999). It functions by 
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inhibiting bacterial replication rather than killing them and so it is defined as 
bacteriostatic (Collignon & Tumidge, 1999). The mechanism of action for fusidic acid is 
the inhibition of bacterial protein synthesis (Collignon & Tumidge，1999). It does so by 
interfering the elongation factor G (EF-G) (Collignon & Tumidge, 1999). EF-G is an 
essential protein of bacteria that facilitates the translocation of the tRNA and mRNA 
down the ribosome after the peptide bond formation during the translation process 
(Collignon 8c Tumidge, 1999). Fusidic acid binds to the EF-G, prevents further 
elongation and thus inhibits protein synthesis (Collignon & Tumidge，1999). 
1.6.7 Clindamycin 
Clindamycin is a lincosamide antibiotic (Spizek et al., 2004). It has an unusual spectrum 
of being active against Gram-positive aerobic bacteria, anaerobic bacteria and some 
•‘ protozoa but not Gram-negative aerobic bacteria (Spizek et al., 2004). It inhibits protein 
synthesis by binding to the 23 S rRNA of the SOS subunit of the bacterial ribosome, 
interfering with the initiation of translation (Spizek et al., 2004). 
令 
1.7 Hypothesis 
According to previous findings, it was found that necrotizing pneumonia caused by PVL-
producing S. aureus has a mortality rate of 75% and PVL-expressing strains are 
frequently associated with complications (Dumitrescu et al., 2008). It was also shown 
that sub-inhibitory concentration of p-lactams affects PVL production in S. aureus 
(Dumitrescu et al., 2008). For example, subinhibitory concentration of oxacillin increased 
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PVL protein production of S. aureus (Dumitrescu et al., 2008). This suggests that the 
effect of antibiotics on PVL toxin release should be considered when decision of the use 
of antibiotics for the treatment of PVL-positive staphylococcal infection is made 
(Dumitrescu et al., 2008). Moreover, the mortality rate 48hr after admission for patients 
infected with PVL-positive S. aureus has been shown to be much higher than for those 
infected with PVL-negative strain (37% for PVL-positive patients and 6% for PVL-
negative patients) (Gillet et al , 2002). This indicates that the PVL toxin may enhance the 
mortality rate of staphylococcal infection (Gillet et al., 2002). Understanding the drugs 
that affect its expression will be a requisite in the choice of treatment in P.VL-producing 
CA-MRSA infections. The choice of antibiotics that minimizes release of PVL may 
reduce severity of disease and improve treatment outcome in CA-MRSA infections. 
The objectives of this study is to investigate the in vitro and in vivo effects of commonly 
used antibiotics e.g. ciprofloxacin, gentamicin, levofloxacin, vancomycin, clindamycin, 
fusidic acid and linezolid on pvl gene expression in CA-MRSA in Hong Kong. Novel 
virulence factors, phenol soluble modulins (PSMs-al-4), have also been reported to 
demonstrate cytolytic activities implicated in CA-MRSA infections and will also be ‘ 
examined. Dumitrescu et al demonstrated pvl gene expression would be altered by 
different antibiotics using a laboratory S. aureus reference strain lyzogenized by phage 
phiSLT (encoding PVL) and they measure PVL expression at the total accumulated 
protein level collected at the stationary phase (Dumitrescu et al., 2008). In this study, the 
effect of antibiotics on PVL and PSMs mRNA expression at different growth phase will 
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be investigated. In addition, the effect of antibiotics on necrotizing pneumonia in mice 
will also be demonstrated. 
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Chapter 2 Methods and Materials 
2.1 Bacterial isolate 
A representative strain of CA-MRSA (Southwest Pacific clone, ST30, spa t019) prevalent 
in Hong Kong (Lab no. 40239 from 2008, isolated from a pus swab specimen) was used 
throughout the study for the in vitro and in vivo experiments. The characteristics of this 
strain are shown in Table 2.1. The minimum inhibitory concentrations (MICs) of the 
seven antibiotics, including vancomycin, linezolid, ciprofloxacin, . fiisidic acid， 
levofloxacin, gentamicin and clindamycin for the isolate were determined using the 
microbroth dilution method according to the Clinical Laboratory Standards Institute 
(CLSI, 2008). A growth curve of the strain in BHI broth at 37 °C was determined to 
ascertain the points of harvest for mRNA measurements (Figure 3.1). 
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Table 2.1 Characteristics and minimum inhibitory concentrations (MICs) of seven antibiotics, including 
Vancomycin, linezolid, ciprofloxacin, fusidic acid, levofloxacin, gentamicin and clindamycin on CA-MRSA 
strain (Southwest Pacific clone, ST30, spa t019). 






































No CLSI guideline 
Piperacillin 256 
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Cefoperazone/Sulbactam (2:1) 32 
Pefloxacin 0.5 
Nalidixic acid >64 
Ceftibuten >128 
Cefotaxime/Clavulanic acid >64 
Cefpirome 32 
Fusidic acid o 25 
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2.2 Effect of subinhibitory antibiotics on the expression of mRNA 
in MRSA in vitro 
2.2.1 Collection of bacterial fraction 
A single colony of MRSA subcultured from a glycerol stock was inoculated into 10 ml 
brain heart infusion broth (BHI), incubated at 37 °C overnight with shaking at 220 rpm. 
One milliliter of the overnight culture was added into 100 ml BHI, which was then 
incubated at 3 7 � C with shaking at 220 rpm until ODeoo reached 0.3. An antibiotic, at 1/8 
MIC, was added to the broth as the previous study done by Dumitrescu et al. found that 
PVL production was up-regulated most at this concentration of antibiotics . Aliquots in 
10 ml of the culture were collected at OD 0.3 (before addition of antibiotic), 0.6, 1.8，2.1 
and 2.3 representing the early log phase, the log phase, the late log phase, the early 
stationary phase and the stationary phase respectively. The cells were harvested by 
centrifugation at 4 with 3500 rpm for 10 mins and the pellet was resuspensed with the 
RNAprotect Bacteria Reagent (Qiagen, USA) and incubated at room temperature for 5 
mins. Centrifugation was performed at 4 °C with 3500 rpm for 10 mins to collect the 
pellet, which was then stored at -80 °C for RNA extraction. A broth without antibiotics ‘ 
was used as a control. 
2.2.2 RNA extraction and DNA digestion 
Total RNAs were extracted from the bacterial cells using the RNeasy Mini "Kit (Qiagen, 
USA). 200 TE buffer (10 mM Tris-Cl, 1 mM EDTA，pH 8) containing 8 mg/ml 
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lysozyme was added to the pellet, which was then vortexed for 10 seconds and incubated 
at room temperature for 5 minutes. Subsequent procedures were then carried out in 
accordance to the manufacturer's protocol. 
The extracted RNA was treated with DNase to remove contaminating DNA using the 
TURBO DNA-free kit (Ambion，USA). Five microliter of the lOX TURBO DNase 
Buffer and 1 \il TURBO DNase (2 units/fxl) were added to the RNA and mixed gently. 
The reaction was incubated at 37°C for 30 minutes. Then, 5 pi resuspended DNase 
Inactivation Reagent was added to the tube and mixed well. The tubes were incubated at 
room temperature for 2 minutes, with mixing occasionally, and subsequently centrifuged 
at 10，000x g for 1.5 minutes. The supernatant was then transferred to a new tube. 
The RNA was quantified with the use of a Nanodrop spectrophotometer and the RNA 
quality was assessed by 2% agarose gel electrophoresis. A check of DNA contamination 
after DNase treatment was performed by quantitative PGR using the 16S primers and the 
thermal cyclic conditions and procedures were the same as the ones described in section 
2.2.4. ‘ 
2.2.3 Reverse transcription for cDNA synthesis 
The total RNA (~200ng/|il) was reversely transcribed to cDNA using SuperScript III 
Reverse Transcriptase (Invitrogen, USA) as according to manufacturer's instructions. 
One microliter random primers (250ng/^il), 1 - dNTP Mix (10 mM) and 11 total RNA 
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were mixed together in an Eppendorf tube and denatured at 65 °C for 5 minutes. The tube 
was immediately placed on ice. A mixture containing 4 |il 5X First-Strand Buffer, 1 p.1 
DTT (0.1 M), 1 nl RNaseOUT Recombinant RNase Inhibitor (40 miits/^il) and l^il 
SuperScriptlll Reverse Transcriptase (200 units/^il) was added to the tube and incubated 
at 25 °C for 5 min, followed by 50 °C for 60 minutes and 70 °C for 15 minutes. 
2.2.4 Quantitative real-time PGR (qPCR) analysis {pvl andpsmal-A 
expression) 
The quantity of pvl, psmal-A and 16S gene expression was determined by the qPCR 
using an ABI Prism 7700 Sequence Detector, Power SYBR Green PGR master mix 
(containing SYBR Green I Dye, AmpliTaq Gold DNA polymerase dNTPs, and passive 
reference ROX dye for normalizaion of well-to-well fluorescent fluctuations) (Applied 
Biosystems, USA) and MicroAmp® Optical 96-Well Reaction Plate (Applied 
Biosystems, USA). Each reaction contained 12.5 \i\ Power SYBR Green PGR master mix, 
0.5 |xl forward primer (10 [rni), 0.5 \i\ reverse primer (10 \im), 5 jil lOOOx diluted cDNA 
and 6.5 nuclease-jfree water to make up a total volume of 25 \i\ for 16S gene detection. 
For pvl (luk-S) gene detection, the reaction contained 12.5 \l\ Power SYBR Green PGR 
master mix, 0.75 \i\ forward primer (10 nm), 0.5 pi reverse primer (10 |im), 5 |il lOx 
diluted cDNA and 6.25 \i\ nuclease-free water. The thermal cyclic conditions for 
amplification of the 16S gene were 95 °C 10 mins，40 cycles of 95 °C 15 sec, 58 °C 30 
sec and 72 °C 30 sec while that of the pvl gene were 95 °C 10 mins, 40 cycles of 95 °C 
15 sec, 50 °C 30 sec and 72 °C 30 sec. PGR conditions for amplification of the psmal-4 
were 95 10 mins, 40 cycles of 95 °C 15 sec, 60 °C 30 sec and 72 °C 30 sec. Negative 
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control was included in each run in which nuclease-free water was added to the reaction 
cocktail instead of cDNA template. Control standards containing to 10^  copies of the 
16S gene were included in the 16S gene amplification reaction while for the pvl and 
psmalA genes, standards containing 10^  to 10^  copies of the gene were included. The 
preparation of the standards for the two genes was described in section 2.1.5. All samples 
were triplicated. Results were analyzed with the software Sequence Detection System 
version 1.9.1. The baseline range and the threshold level were adjusted to achieve the 
standard curve with the highest correlation coefficient The copy numbers of the 
triplicated samples were extrapolated from the standard curve and averaged. The p\l and 
psmalA expression was then determined by the copy number ratio (pvl orpsmal-4 copy 
number/；copy number). The 16S rRNA acted as an internal control for normalization 
of the pvl expression. The primers used in the qPCR are shown as follows: 
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Table 2.2 Primer sequences for amplification of pvl and psmal-4 genes 
Gene Primer Genebank Amplicon 
accession size 
no./Reference 
F: 5'TCGTGTCGTGAGATGTTG3' R i o r d a n e t a l 1 8 8 ^ 
2006 
R: 5'CTGCCCTTTGTATTGTCC3‘ 
pvl (luk-S): F: 5'TGAGGTGGCCTTTCCAATAC3' CP000255 160 bp 
R: 5'CCTCCTGTTGATGGACCACT3' 
psmal F: 5‘ ATGGGTATCATCGCTGGCA 3， BK006301 66 bp 
R: 5'TTATTTACCAGTGAATTGTTCGATTAAGC 3' 
psmal F: 5'ATGGGTATCATTGCAGGAATCA 3' 
R: 5'TTACTTACCAGTGAATTTCTCAATTAATCCT 3’ 
psmo3 F: 5'ATGGAATTCGTAGCAAAATTATTCAA 3' 
R: 5 TTAGTTGTTACCTAAAAATTTACCAAGTAAATC~ 
3， 
psmoA F: 5'ATGGCTATTGTAGGTACTATCATTAAAATCA 3 ' ^ 
R: STTATTTTGCGAAAATGTCGATAATT 3' . 
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The in vitro experiment was repeated for 3 times such that the average and standard 
deviation of the copy number ratio {pvl or psmalA copy n u m b e r " c o p y number) can 
be calculated. 
2.2.5 Preparation of standard controls for quantification ofDNA copy 
number in qPCR reactions 
The 16S, pvl and psmalA genes were cloned using the TOPO® TA cloning kit 
(Invitrogen, USA) to produce standard copy controls for the qPCR reaction. Firstly, 
PCRs were carried out to amplify the 16S, pvl andpsma\-4 genes using their respective 
forward and reverse primers. The reaction mixtures and conditions for these genes are 
shown as follows: 5 i^l lOX PGR buffer, 4 i^l MgCl! (25 mM), 1 \i\ dNTP (10 mM), 1 \ii 
Forward primer (10 pm), 1 |il Reverse primer (10 ^m)，0.5 |xl Taq polymerase (1 unit/jxl), 
34.5 \l\ Water, 3 |il DNA template to make up a reaction with 50 |xl total volume and the 
PGR conditions for the 16S and pvl genes are 95 °C 10 mins, 40 cycles of 94 °C 30s, 55 
°C 30s，72 °C 30s, and 72 ®C 5 mins while the PGR conditions for the psmal-4 genes are 
95 °C 10 mins, 40 cycles of 94 30s，60 °C 30s，72 °C 30s, and 72 °C Smins 
The size of the PGR products were confirmed by agarose gel electrophoresis and the PGR 
products were cloned into the pCR®2.1-T0P0® vector using the TOPO® TA cloning kit 
(Invitrogen, USA). Four microliter PGR product, 1 \l\ salt solution and 1 iil TOPO® 
vector were mixed and incubated for 5 minutes at room temperature. 2 i^l of this reaction 
was added into a vial of One Shot® Chemically Competent E. coli and mix gently. The 
reaction was incubated on ice for 30 minutes and the cells were heat-shocked for 30 
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seconds at 42 °C without shaking and were immediately transferred to ice. Two hundreds 
and fifty microliter of room temperature S.O.C. medium was added and the mixture was 
shaked at 200 rpm at 37 °C for 1 hour. Fifty microliter of the transformation reaction was 
spread on a prewarmed selective LB plate (containing 100 ng/ml ampicillin) and the plate 
was incubated overnight at 37 °C. Colonies were picked and subcultiired in LB broth 
(containing lOO^g/ml ampicillin) at 37 °C overnight. A colony PGR check for the 
successful cloning was carried out using Ml 3 forward and reverse primers. The PGR 
conditions were 95 °C 10 mins, 40 cycles of 94 °C 30sec 55 °C 30sec and 72 °C 40sec, 
followed by 72 °C Smins. The PGR products were run in gel electrophoresis to confirm a 
single band. The overnight culture was centrifuged at 3500 rpm at 4 °C to collect the 
pellet. The plasmid DNA was extracted and purified from the bacterial pellet using the 
QIAprep Miniprep kit (Qiagen，USA)，following the procedures of the kit. 
PCRs were performed to fiirther confirm the target gene being cloned into the plasmid 
using the respective forward and reverse primers of the target genes. PGR conditions for 
the 16S and pvl genes were 95 °C 10 mins, 40 cycles of 94 °C 30s, 55 °C 30s, 72 °C 30s, 
and 72 °C 5mins while the PGR conditions for the psmalA genes were 95 °C 10 mins, 
40 cycles of 94 °C 30s，60 30s, 72 °C 30s，and 72 °C Smins. 
The absorbance of the recombinant plasmid was measured with the use of a Nanodrop 
spectrophotometer. Using the formula 1 ^g=6.02*10'V660(N) copies, where N is the 
number of nucleotides, the concentration of the recombinant plasmid (in ng/^il) can be 
converted to the copy number of the genes. Then, the recombinant plasmids of the genes 
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were serially diluted to make a set of standard ranging from 10-10^ copies for the qPCR 
reaction. 
2.3 Effect of subinhibitory concentration of antibiotics on MRSA 
pneumonia in a murine model 
6-week-old female BALB/c mice were ear-tagged and divided into groups. Groups of 3 
mice were kept in individually ventilated cages (IVCs) for 3 days prior to inoculation. 
600 \i\ overnight culture of CA-MRSA was subcultured into 60 ml BHI broth, which was 
then incubated at 37 °C with shaking until OD=0.3 (cfu~l*10V ml). Bacterial cells were 
harvested by centrifliging at 2500 ipm, 10 mins at 4 °C. The supernatant was discarded 
and the pellet was kept on ice, and resuspended in 600 |il cold BHI and saved at 4 °C 
until use. Bacterial counts were performed by removing 10 pi and serially diluted and 
each dilution was plated out on blood agar for counting. 
The mice were anesthetized with ketamine/xylazine mixture (0.5 ml ketamine, 0.25 ml 
xylazine and 4.25 ml water) and all mice of the infected group were infected intranasally 
with a 10 inoculum (-10^ cfu) of CA-MRSA. Control mice were given the equivalent 
volume of sterile BHI broth. For the drug-treated group, subinhibitory concentration of 
antibiotics (1/2 MIC), calculated based on the body weights of the mice, was 
administered orally (for ciprofloxacin, gentamicin, levofloxacin, clindamycin, fusidic 
acid and linezolid) or intraperitoneally (for vancomycin) 2 hour after the inoculation. The 
inoculum and sacrifice time were optimized to be � lO? cfu and 24 hours such that 
pneumonia disease was developed and at the same time the mice were neither being 
killed nor getting recovered and the effect of drugs on pneumonia can hence be studied. 
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The mice were sacrificed after 24 hours by cervical dislocation and the lung, liver and 
spleen tissues were removed. A piece of each tissue was cut, weighed and homogenized 
with 250 |il phosphate buffered saline (PBS). Bacterial counts were performed by serial 
dilution and plating onto blood agar for colony counts. The remaining tissue samples 
were placed in formalin and sent to an independent histopathologist at the Department of 
Anatomical and Cellular Pathology of The Chinese University of Hong Kong for 
histological examination, where the lung tissue was paraffin-fixed, sectioned, mounted on 
a slide and stained with hematoxylin and eosin. The severity of pneumonia was 
determined and graded by the histopathologist according to the levels of leukocyte and 
erythrocyte infiltration, alveolar integrity and epidermis damage, as modified from 
(Labandeira-Rey et al., 2007), to as stated below: 
0=no lesions, no leukocyte or erythrocyte infiltrate, normal epithelia 
l=as 0，except some leukocyte infiltration 
2=as 0，some leukocyte and erythrocytes in the airspace but the alveolar structure is , 
preserved. 
3=1 or 2 lesions smaller than SOOiim in length/width or many smaller ones. Some 
leukocyte and erythrocyte infiltrate in the alveoli, but the alveolar structure is preserved. 
No epithelial damage. 
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4=less than 3 lesions smaller than l,000|am in length/width; leukocytes and erythrocytes 
throughout the lesion. Alveolar structure not preserved within the lesion. Some epithelial 
damage. 
5a= more than 3 lesions OR l,000[im in length/width; leukocytes and erythrocytes 
throughout the lesion. Alveolar structure not preserved within the lesion. Damage 
epithelium. 
5b= more than 3 lesions AND 1,000pm in length/width; leukocytes and erythrocytes 
throughout the lesion. Alveolar structure not preserved within the lesion. Damage 
epithelium. 
For each experiment with an antibiotic, there were 2 groups of mice: the infected group 
， and the infected group with drug delivery, plus a control without infection and drug 
treatment. Each group contains 6 mice. The in vivo experiment was repeated for 3 times 
such that the mortality rate of mice after 24 hrs and the percentage of scores of lung 
histology can be calculated. , 
2.4 Statistical Analysis 
Statistical significances of the differences in both the in vitro and in vivo experiments 
were determined by Student's t test. P-value < 0.05 would be considered as a significant 
difference. 
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Chapter 3 Results 
3.1 Effect of subinhibitory antibiotics on the expression of mRNA 
in MRSA in vitro 
CA-MRSA was subcultured in BHI broth and subinhibitory concentration of antibiotic 
was added at the early log phase (OD 0.3) of bacterial growth. Culture fractions were 
collected at OD 0.3 (before the addition of antibiotic), 0.6, 1.8，2.1 and 2.3, representing 
early log phase, log phase, late log phase, early stationary and stationary phases 
respectively. Figure 3.1 showed the growth curve of this strain and it remained the same 
in the presence of all antibiotics. Total RNAs were extracted and reversely transcribed 
into cDNA. Real-time PGR was then carried out to determine the PVL and PSMal-4 
expression level, which was normalized with the internal control 16S ribosomal RNA. 
Figure 3.2 shows an example of a plot of threshold cycle (Ct) against copy number of 
target gene and figure 3.3 shows the effects of seven antibiotics on PVL expression. 
Ciprofloxacin demonstrated a significant increase in PVL expression at the early , 
stationary and stationary phases. Both linezolid and fusidic acid exhibited a significant 
increase in PVL expression at the late log and early stationary phases. For gentamicin and 
levofloxacin, the PVL expression is significant higher across the late log, the early 
stationary and the stationary phases. There is only a significant increase in PVL 
expression at the early stationary phase for the vancomycin group. Clindamycin does not 
show a significant increase in PVL expression at all phases. 
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The effects of the seven antibiotics on PSMal expression are demonstrated in figure 3.4. 
All drugs induced the expression of PSMal, but at different phases. Clindamycin and 
linezolid increased the PSMal expression from OD 0.6 to 2.3 while gentamicin induced 
the expression from OD 0.6 to 2.1. Fusidic acid showed the increase in expression at OD 
1.8 and 2.1 and there was an increase in expression from OD 1.8 to 2.3 for levofloxacin. 
An increased expression was seen at OD 2.1 and 2.3 for ciprofloxacin while vancomycin 
only had an increased expression at OD 2.1. 
Figure 3.5 shows PSMa2 expression under the effects of the antibiotics. Clindamycin had 
an increased expression from OD 0.6 to 2.1 while linezolid showed the increase from OD 
1.8 to 2.3. Gentamicin increased the PSMa2 expression at OD 1.8 and 2.1 and 
levofloxacin increased the expression at OD 2.1 and 2.3. Other antibiotics did not 
demonstrate an increased expression. 
From figure 3.6, all antibiotics increased the expression of PSMa3 at different phases. All 
of them had an increased expression at OD 2.1 (except vancomycin) and 2.3. Fusidic acid, 
gentamicin and linezolid showed an increase in expression at OD 1.8 and there was only ‘ 
gentamicin showing the increased effect at OD 0.6. 
For the effects of antibiotics on PSMa4 expression (figure 3.7), all drugs increased the 
expression at OD 1.8 (except ciprofloxacin), 2.1 and 2.3. At OD 0.6，only vancomycin 
and clindamycin showed the increase in PSMa4 expression. 
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Figure 3.1 Growth curve of CA-MRSA (Southwest Pacific clone, ST30, spa t019). CA-
MRSA was subcultured in BHI broth and subinhibitory concentration of antibiotic was 
added at the early log phase (OD 0.3) of bacterial growth. Culture fractions were 
collected at OD 0.3 (before the addition of antibiotic), 0.6，1.8, 2.1 and 2.3, representing 
early log phase, log phase, late log phase, early stationary and stationary phases 
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Figure 3.2 Standard curve of threshold cycle against copy number of target gene. The 
quantity of pvl, psmalA and 16S gene expression was determined by the qPCR reaction. 
., Results were analyzed with the software Sequence Detection System version 1.9.1. The 
baseline range and the threshold level were adjusted to achieve the standard curve with 
the highest correlation coefficient. The copy numbers of the triplicated samples were 
extrapolated from the standard curve and averaged. The pvl and psmal-4 expression was 
then determined by the copy number ratio {pvl or psmalA copy n u m b e r " c o p y 
number). The 16S rRNA acted as an internal control for normalization of the pvl and 
psma 1 -4expression. 
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Effects of antibiotics on PVL expression 
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Figure 3.3 Effect of antibiotics on PVL expression. PVL expression was up-regulated in 
vitro to different extent by different classes of antimicrobials, as compared to the control 
group. Values are means 土 SD of three different experiments *denotes a statistically 
I 
significant increase (p<0.05) compared with the control at the same time point. The effect 
is most marked with ciprofloxacin 
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Figure 3.4 Effect of antibiotics on PSMal expression. Values are means 土 SD of three different 
experiments *denotes a statistically significant increase (p<0.05) compared with the control at 
the same time point. 
68 
Effects of antibiotics on PSMal expression 
0.009 -| 
i • 




„ „ „ 产 _ • control 
0 0.006 ffl-
冬 _ • vancomycin 
. 0 005 I j L • clindamycin 
y f • • fusidic add 
1 0.004 1 1 1 •gentamycin 
0 T • • l l l l l l l • levofloxacin 
0.003 X — a ciprofloxacin 
1 
I 0.6 1.8 2.1 2.3 
Bacterial growth phase at OD(oo 
Figure 3,5 Effect of antibiotics on PSMa2 expression. Values are means 土 SD of three different 
experiments ^denotes a statistically significant increase (p<0.05) compared with the control at 
the same time point. 
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Figure 3.6 Effect of antibiotics on PSMa3 expression. Values are means 土 SD of three different 
experiments *denotes a statistically significant increase (p<0.05) compared with the control at 
the same time point. 
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Figure 3.7 Effect of antibiotics on PSMa4 expression. Values are means 土 SD of three different 
experiments *denotes a statistically significant increase (p<0.05) compared with the control at 
the same time point. 
71 
* 
table 3.1 Effects of seven antibiotics on PVL and PSMal-4 expression compared with the control. +: increase, 
no significant difference, decrease. 
OD OD 
Antibiotic Antibiotic ~ - — ~ — ” 
, 0.6 1.8 2.1 2.3 0.6 1.8 2.1 2.3 
• j^comycin Gene Levofloxacin Gene 
PVL - 0 + 0 PVL - + + + 
PSMal 0 0 + 0 PSMal + + + 
PSMa2 - - 0 - PSMa2 - o + + 
PSMa3 0 0 0 + PSMa3 o + + 
‘ ^ PSMa4 + + + + PSMa4 + + + 
, OD OD 
Antibiotic Antibiotic 〃 一 „ , 相 — 
、 ^ 0.6 1.8 2.1 2.3 0.6 1.8 2.1 2.3 
Clindamycin Gene Ciprofloxacin Gene 
PVL 0 0 0 - PVL o 0 + + 
PSMal + + + + PSMal o o + + 
PSMa2 + + + o PSMa2 o o o o 
PSMa3 0 0 + + PSMa3 o o + + 
PSMa4 + + + + PSMa4 - - + + 
, OD OD 
^ ^ 0.6 1.8 2.1 2.3 A- io t ic 0.6 1.8 2.1 23 
,Qentamicin Gene Linezolid Gene 
PVL + + + PVL + + 0 
、 PSMal + + + o PSMal + + + + 
PSMa2 0 + + o PSMa2 o + + + 
^ PSMa3 + + + + PSMa3 o + + + 
‘ PSMa4 0 + + + PSMa4 + + + 
Antibiotic 
. 、 0.6 1.8 2.1 2.3 
j ^ d i c acid Gene 
PVL + + o 
PSMal 0 + + 0 
^ PSMa2 - 0 0 -
PSMa3 0 + + + 
1 I PSMa4 + + + 
t ^ 1 1 
I • 
！ • • 
i 
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Table 3.2 PVL and PSMal-4 expression ratio of different antibiotics compared with 
control at the same OD 
P ^ " " “ P S M o l P S M a 2 P S M a 3 P S M a 4 
expression expression expression expression expression 
ratio ratio ratio ratio ratio 
compared compared compared compared compared 
Antibiotic OD with control with control with control with control with control 
Ciprofloxacin 0.6 T j ] T ^ 
1.8 1.29 1.31 0.98 165 0.71 
2.1 2.24 3.19 1.45 2.50 2.47 
4.95 
Linezolid 0.6 0.60 1.84 0.86 1.35 033 
1.8 1.77 2.69 1.54 3.45 3.68 
2.1 1.83 7.06 2.84 7.58 6.92 
17.26 
Fusidic acid 0.6 0.45 1.08 0.68 067 040 
1.8 1.47 1.70 1.07 163 • 3.93 
2.1 1.70 2.46 0.97 1.86 3.99 
7.62 
Gentamicin 0.6 0.55 1.46 1.35 ？55 i T i 
1.8 1.55 2.12 2.45 3.22 7.98 
2.1 1.34 3.78 2.32 4.27 8.55 
23 1J7 2.94 15.21 
Levofloxacin 0.6 0.53 0.29 0.38 0^7 034 
1.8 1.50 1.41 1.19 1.24 3.86 
、 2.1 1.99 2.15 2.42 2.96 5.47 
17.30 
Vancomycin 0.6 0.61 
1.8 1.03 0.83 0.59 0.88 5.46 
2.1 2.08 1.44 0.81 1.07 4.21 
8.57 
Clindamyclin 0.6 1.05 1.69 1.41 ~ 
1.8 0.91 1.79 1.34 1.33 2.89 
2.1 1.01 3.19 1.94 3.19 4.29 
2.3 I 0.54 2.03 1.14 3.23 8.76 
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3.2 Effect of subinhibitory concentration of antibiotics on MRSA 
pneumonia in a murine model 
For optimization, inoculums of 1x10^ cfu/ml, 2.5x10^ cfu/ml, 5x10^ cfu/ml, 9.35x10^ 
cfii/ml and 1.865x10^® cfii/ml were tried and 1x10^ cfu/ml was chosen for inoculation 
since under such inoculum the infected control group (without antibiotics delivery) had a 
low mortality rate such that the effect of antibiotics on pneumonia could be more clear-
cut. For the duration of harvest, 1-3 days were tried and 24 hrs after infection was chosen 
as the harvest time since the pneumonia scores of mice harvested in days 2 and 3 were 
generally lower than those harvested in day 1. 
As expected, there was bacterial growth in the lung of mice in the range of 10-10^ cfu/mg 
tissue, while dissemination into liver or spleen occurred in the majority of cases. The 
quantity harvested in the latter sites ranged from 0-100 cfii/mg tissue. 
Table 3.3 shows the mortality rate of mice treated with different antibiotics. The 
mortality rate is the highest for ciprofloxacin (83%), which is significantly higher than 
the control group (without antibiotic treatment) while that of clindamycin and fusidic acid 
also have a significantly higher mortality rate compared with the control, 50% and 33% 
respectively. For other antibiotics, including linezolid, vancomycin, gentamicin and 
levofloxacin, there is no significant difference in mortality rate compared with the control. 
From Figure 3.8, the normal lung from the non-infected control group is healthy and 
pinkish. However, for the lungs isolated from the infected group, red patches suggesting 
congestion with haemorrhages and necrosis appear on the lung, which is a phenomenon 
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of necrotizing pneumonia due to epithelial damage and infiltration of erythrocytes. Lungs 
which were deep red in colour were observed in the infected mice with severe pneumonia. 
Those mice with these lungs are usually dead within the 24 hours. 
Figures 3.9 and 3.10 show the macroscopic appearance and histological sections of lung 
tissue. Normal lung architecture showing alveoli and airspace is observed in the lung 
section of the (a) non-infected control group, whilst the infected are shown in (b) and (c) 
in severe pneumonia group. However, for the infected lung with grade 5 pneumonia, 
inflammatory lesion larger than 1000^im in width was observed in the histological section 
and there was infiltration of leukocytes and erythrocytes due to epithelial damages, 
resulting in the absence of airspace. 
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Figure 3.8 The macroscopic appearance of lungs isolated from mice of the (a) control and 
(b) &(c) infected groups, (a) The normal lung from the non-infected control group is 
pinky in colour, (b) However, for the lungs isolated from the infected group, red patches 
�appear on the lung, which is a phenomenon of necrotizing pneumonia due to epithelial 
damage and infiltration of erythrocytes, (c) Lungs which are in deep red in colour are 




》） (b) (c) 
Figure 3.9 The macroscopic appearance and histological sections of lung tissue, (a) Normal lung of non-infected 
control group; (b) Normal lung architecture showing alveoli and air sacs, H&E, xlOO; (c) Normal lung architectfire 
showing alveoli and air sacs, H&E，x400. Normal airspace was observed without infiltration of erythrocytes 铁nd 
leukocytes. mmm 
f ) (b) (c) 
'Sure 3.10 The macroscopic appearance and histological sections of lung tissue, (a) Infected lung with gradp 5 
Pneumonia; (b) Inflammatory lesion >1000urn in width, H&E，xlOO; (c) Damaged epithelia with leukocytes 铁nd 
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Figure 3.11 The histological sections of lung tissue, (a) Grade 1 pneumonia with some leukocyte 
infiltration，H&E x400. (b)& (c) Lesion less than 500 |im in width, a characteristic of grade 3 pneumonia, 
(b) Lesion less than 500 ^m in width, H&E xlOO (c) Lesion less than 500 i^m in width, damaged epithel^a 
with leukocytes and erythrocytes infiltration, H&E x400. (d) Grade 4 pneumonia with less than 3 lesions smaller than l,000|im in width, H&E x40. (e;i&(f) Lesion greater than 1000 i^m in width, a characteristic ofgrade 5a and 5b p eumonia, (e) Lesion greater than 1000 i^m in width, H&E xlOO. (Q L ion greater than1000 jLim i  width, da age epith l a with l ukocytes and rythrocytes infiltrat on, H&E, x400. (g)Grade79 
5b pneumonia with more than 3 lesions AND l,OOO^ Lm in width, H&E，x40. (h) Normal lung architecture 




Table 3.3 The mortality rate of mice groups treated with various antibiotics and the 
control group. 
Treatment with subinhibitory antibiotics Percentage died p value (Students' t-
(no. of mice) within 24 hours (%) test) 
No antibiotic (42) 17 
Ciprofloxacin (18) ^ <0.05 
Clindamycin (18) 50 
Fusidic acid (18) 33 
Linezolid (18) 22 >0.05 
Gentamicin (18) 22 
Vancomycin (18) 22 
Levofloxacin (18) 22 
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Chapter 4 Discussion 
As CA-MRSA infection has become more prevalent, it is essential to know whether the 
treatment of CA-MRSA with different antibiotics would up-regulate PVL production or 
not since the increased production of PVL will contribute to more severe tissue necrosis. 
This may lead to a situation in which although the bacterial replication is inhibited by the 
antibiotics, the PVL production is induced, extending the condition of tissue damage. 
Moreover, the mortality rate 48hr after admission for patients infected with PVL-positive 
S. aureus has been shown to be much higher than for those infected with PVL-negative 
strain (37% for PVL-positive patients and 6% for PVL-negative patients) (Gillet et al., 
2002). This indicates that the PVL toxin may enhance the mortality rate of staphylococcal 
infection (Gillet et al., 2002). Understanding the mechanism of expression of PVL and its 
production, and the drugs that affect its expression will be a requisite in the choice of 
� treatment in PVL-producing CA-MRSA infections. 
4.1 Effect of subinhibitory antibiotics on the expression of mRNA 
in MRSA in vitro 
The antibiotics used in the in vitro study include ciprofloxacin, levofloxacin, fusidic acid, 
vancomycin, gentamicin, linezolid and clindamycin. The reason for choosing these 
antibiotics is that they represent different classes of drugs targeting the bacteria in 
different ways and exerts different effects. 
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From figure 3.1., for the control, as the OD increases, the relative PVL and PSMal-4 
expressions increase. It is because according to previous studies it was found that PVL 
and PSM expression are upregulated by the accessory gene regulator {agr) quorum-
sensing regulatory mechanism, which functions in a growth phase dependent fashion (Joo 
et al., 2010; Iwatsuki et al., 2006; Sakoulas, 2006). As the cell density increases, it 
triggers the signaling mechanism and cell-cell communication is mediated through the 
exchange of the signaling molecules called autoinducers, leading to the increased PVL 
and PSM gene expression (Joo et al, 2010; Bernardo et al., 2004; Iwatsuki et al., 2006; 
Sakoulas, 2006). 
The effect of antibiotic on PVL expression is the most prominent with ciprofloxacin, 
especially at the early stationary and stationary phases compared with the control at the 
same time point. Levofloxacin is in the same class of antibiotic as ciprofloxacin 
�(Madurga et al , 2008). A similar PVL expression pattern with ciprofloxacin is observed 
for levofloxacin. It is interesting that both ciprofloxacin and levofloxacin are antibiotics 
targeting the DNA gyrase and DNA topoisomerase IV，inhibiting the transcription and 
DNA replication (Drlica & Zhao，1997). However, the amount of the PVL mRNA 
transcripts significantly increases at the early stationary and stationary phases. This may 
be because the modulatory effect of the drug on PVL expression is greater than the 
inhibition effect of the drug. 
Unlike ciprofloxacin, both linezolid and fusidic acid exhibit a significant increase in PVL 
expression in the late log phase and the early stationary phase. They are both bacterial 
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protein synthesis inhibitors (Moellering, 2003; Collignon & Tumidge，1999). Linezolid 
targets on the first step, initiation, of the protein synthesis by binding to the 23 S 
ribosomal RNA of the SOS subunit of the ribosome (Moellering, 2003). On the other 
hand, fiisidic acid targets on the elongation step of protein synthesis by interfering the 
elongation factor G and hence the translation process (Collignon & Tumidge, 1999). 
From the result it was found that no matter the target of the drug is on the initial step or 
the elongation step of translation, a significant increase in PVL expression is observed in 
the late log phase and the early stationary phase. Although gentamicin is also a bacterial 
protein synthesis inhibitor, it shows a significant increased PVL expression across the 
late log, early stationary and stationary phases, which is different from linezolid and 
fusidic acid. This different modulatory effect on PVL expression may be explained by the 
different mode of action of the drug, which interferes bacterial protein synthesis by 
binding to the 308 subunit of the ribosome rather than the SOS subunit or the elongation 
�factor G (Leggett, 1990). This may thus lead to a different pathway exerting a different 
modulatory effect on PVL expression. 
Vancomycin just exerts a significant effect in the early stationary phase. This may 
suggest that cell-wall acting antibiotic may result in a less inducible effect on PVL 
expression. Among these antibiotics, clindamycin is the only one that does not cause a 
significant increase in PVL expression compared with the control and at the stationary 
phase it even exerts an inhibitory effect. It seems that clindamycin is the choice of 
antibiotics for treatment of CA-MRSA infetion. Despite this, the use of clindamycin may 
also be a risk in the treatment of some CA-MRSA strains as the resistance to this drug 
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can be inducible (Lewis II and Jorgensen, 2005). Inducible clindamycin resistance may 
occur in erythromycin resistant CA-MRSA (Lewis II and Jorgensen, 2005). It is because 
there are two major mechanisms that lead to the resistance of a class of antibiotics called 
macrolides (in which erythromycin belongs to this class of antibiotics) (Lewis II and 
Jorgensen, 2005). The first mechanism involves the efflux pump encoded by the msr(A) 
gene which expels macrolides from the cell and this resistant mechanism leads to 
macrolide resistance only (Lewis II and Jorgensen, 2005). The second mechanism 
involves the modification of the antibiotic binding site on the ribosome mediated by the 
methylation of the 23S rRNA (Lewis II and Jorgensen, 2005). This methylation is 
conferred by the erm(C) or erm(A) genes and this resisance mechanism leads to not only 
macrolides resistance, but also to lincosamides (such as clindamycin) and group B 
streptogramins resistance (Lewis II and Jorgensen, 2005). This resistance is referred to as 
MLSB resistance (Lewis II and Jorgensen, 2005). It was found that in several clinical 
�cases of S. aureus infection the patient initially responseded well to the treatment of 
clindamycin (Lewis II and Jorgensen, 2005). However, the infection relapsed in a later 
time, with the isolation of MLSB MRSA demonstrating resistance to clindamycin (Lewis 
II and Jorgensen, 2005). Thus, the use of clindamycin for treatment of erythromycin-
resistant CA-MRSA may lead to inducible clindamycin resistance and complicate the 
treatment further (Lewis II and Jorgensen, 2005). Based on the in vitro findings, it was 
proven that different antibiotics alter PVL expression and so in vivo study was then 




According to the results done by the research group Dumitrescu et al, which investigates 
the effect of different antibiotics on PVL production by a S. aureus at the protein level, 
they found that at 1/8 MIC vanomycin, linezolid and fusidic acid have no effect on PVL 
protein production while clindamycin shows an inhibitory effect compared with the 
control (no antibiotic) (Dumitrescu et al., 2007 and 2008). They did so by using the 24 hr 
culture supernatant and ELISA to detect the PVL protein level (Dumitrescu et al., 2008). 
Their study looked at the effect of antibiotics on the accumulated PVL protein level 
produced by S. aureus at the stationary phase (Dumitrescu et al., 2007 and 2008). In our 
study a different approach was used. We looked at the PVL mRNA transcriptional level 
at different phases of the bacterial growth, giving a snapshot of PVL expression across 
different phases under the effect of different antibiotics. 
The accumulated PVL protein level in the supernatant for vanomycin did not show a 
significant difference compared to the control group in the Dumitrescu et al. investigation 
while our study shows that vancomycin did not show a significant difference in PVL 
expression compared to the control at various time point except at OD 2.1 (Dumitrescu 
et al., 2008). This may be because the significant difference in PVL expression just at the 
early stationary phase may not be sufficient to produce an overall increase in 
accumulated PVL protein production by S. aureus. 
The clindamycin result done by their group is consistent with ours, showing an inhibitory 
effect on PVL production (Dumitrescu et al., 2008). For linezolid and fusidic acid, 
Dumitrescu et al showed that there were no effect at 1/8 MIC (Dumitrescu et al., 2008). 
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However, our results show that there are a significant increase in PVL expression at the 
late log phase and the early stationary phase. There may be some reasons for these 
different results. The first reason may be not all mRNA are translated into protein. There 
may be some post-transcriptional events that may result in this. For example, since 
linezolid and fusidic acid are both the inhibitors of translation, the total PVL mRNA may 
not be fully translated into PVL protein. Another reason may be because different MRSA 
strains and different approaches targeting different levels (cumulated protein level and 
transient RNA level) were used in two different experiments and so the PVL expression 
patterns from two studies may not be directly comparable. 
In the report published by Herbert et al., they demonstrated that subinhibitory 
concentration of clindamycin essentially blocked nearly all exoproteins production, 
including protein A，alpha-hemolysin and serine protease at the transcriptional level 
�(Herbert et al., 2001). They suggested that this inhibitory effect is due to the inhibition of 
the synthesis of one or more regulatory proteins that regulate the transcription of these 
exoprotein genes (Herbert et al., 2001). Compared with our result, we have also found 
that clindamycin exhibits an inhibitory effect on PVL expression at the stationary phase 
in the in vitro study, suggesting that PVL may also be under the same regulation as other 
exoproteins. They also showed that although subinhibitory concentration of clindamycin 
inhibited the expression of exoproteins, the production of certain surface protein, such as 
coagulase and fibronectin binding protein B was stimulated (Herbert et al., 2001). This 
may explain why the mortality rate of mice is significantly higher for the clindamycin 
group than the control group though the in vitro result shows an inhibitory effect on PVL 
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expression. Other factors that may be involved in the cause of necrotizing pneumonia 
may be stimulated by clindamycin. 
From a previous study, a group of researchers found that both linezolid and clindamycin 
induced PVL mRNA expression but suppressed PVL protein production (Stevens et al., 
2007). They proposed the reason for this is due to their mechanism of action, that is the 
inhibition of protein synthesis (Stevens et al., 2007). They also found that vancomycin 
could up-regulate PVL mRNA expression and had little effect on PVL protein production 
compared with the no drug control group (Stevens et al., 2007). They therefore suggested 
that protein synthesis inhibitors such as linezolid and clindamycin are more beneficial 
than vancomycin in terms of treatment outcome and should be considered in treatment of 
MRSA infection (Stevens et al., 2007). 
The upregulation of PVL mRNA expression result for linezolid and vancomycin is 
consistent with our in vitro result, but not for clindamycin. Also they pointed out that 
both linezolid and clindamycin suppressed PVL protein production and vancomycin led 
to a slightly higher PVL protein production compared with the control. From our in vivo 
result, the mortality rate of mice treated with linezolid and vancomycin indeed has no 
significant difference compared with the control group, and this is consistent with their 
results. However, for clindamycin the mortality rate is significant higher than the control 
group in the present study. Therefore, it seems that not all protein synthesis inhibitors, at 
least for clindamycin, would result in a better treatment outcome than vancomycin, taken 
the consideration of both in vitro and in vivo results of this study. 
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4.2 Effect of subinhibitory concentration of antibiotics on MRSA 
pneumonia in a murine model 
Our in vivo results are consistent with the results done by the research group Labandeira-
Rey et al, though we have yet not proven the role of PVL in necrotizing pneumonia. 
Unlike what the research group Loffler et al. has done, where they demonstrated that 
PVL can only cause rapid apoptosis in human and rabbit neutrophils, but fail in murine 
and monkey neutrophils, our results do demonstrate the differences in the degree of 
pneumonia and mortality rate between mice treated with different antibiotics and mice 
without antibiotic treatment (Loffler et al., 2010). They investigated the effect of PVL 
using in vitro neutrophil cell lines (Loffler et al.，2010). The advantage of this method is 
that the effect of neutrophil lysis by PVL can be directly assessed but the disadvantage is 
that this method may not fully reflect the role of PVL in the cause of necrotizing 
pneumonia as the in vivo environment may be different from the in vitro one and so the 
results may be different from that using the animal model. Also, different mice strains 
may contribute to the discrepancy in the in vivo results done by different research groups. 
Labandeira-Rey et al., who successfully proved the role of PVL in the cause of 
necrotizing pneumonia, made use of BALB/c mice and in the present study we also use 
BALB/c mice for the in vivo experiment (Labandeira-Rey et al., 2007). For other groups 
who fail to demonstrate the effect of PVL in necrotizing pneumoma, they use different 
mice strains. Voyich et al. used CDl Swiss and Crl:SKHi-HrBR hairless mice while 
Bubeck et al. used C57B1/6J mice, though Wardenburg et al also used BALB/c mice 
(Voyich et al., 2006; Bubeck et al., 2007; Wardenburg et al., 2008). Different strains of 
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mice may have different resistance to MRSA infection or necrotizing pneumonia and this 
may lead to variations in results done by different research groups. 
Although the pneumonia scores of mice of the infected control group and the drug-treated 
infected group did not demonstrate a difference (pneumonia scores were 5a-5b for both 
groups), the mortality rate showed a significant difference. Infected mice treated with 
ciprofloxacin, clindamycin and fiisidic acid have a significantly higher mortality rate than 
the control group (without antibiotic treatment). The mortality rate is the highest (83%) 
for mice treated with ciprofloxacin and this is correlated with the in vitro result. The 
fusidic acid group in vivo result also correlates with the in vitro result, showing a 
significant increase in mortality rate compared with the control group. Given that the in 
vitro result do not demonstrate a significantly higher PVL expression compared with the 
control, however, the in vivo result shows that the mortality rate of the clindamycin group 
� i s significantly higher than the control group. Also, although levofloxacin and 
ciprofloxacin belongs to the same class of drug, levofloxacin did not produce a 
significant difference in mortality rate compared with the control, which is different from 
the result produced by ciprofloxacin. Other antibiotics, including linezolid, gentamicin 
and vancomycin did not result in a significant difference in mortality rate compared with 
the control group, although they produce a significant effect in the in vitro study. This 
may be because PVL is not the only one factor contributing to necrotizing pneumonia. 
Other virulence factors may be involved. 
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Bernardo et al. have carried out a research on the effect of linezolid on exotoxin 
expression in S. aureus (Bernardo et al., 2004). They found that subinhibitory 
concentration of linezolid can reduce the expression of several virulence factor, including 
autolysin, protein A, staphylococcal enterotoxin A (SEA) and SEB and alpha-and beta-
homolysins at the protein level (Bernardo et al., 2004). Although they did not look at 
PVL expression, our in vivo result shows that the mortality rate for the linezolid group 
has no significant difference compared with that for the control group. It seems that 
subinhibitory concentration of linezolid may also have an inhibitory effect on PVL 
protein expression. 
A previous study done by Yanagihara et al. showed that linezolid is more effective 
against PVL-positive MRSA infection than vancomycin (Yanagihara et al., 2009). They 
used a mouse model to compare the efficacies of linezolid and vancomycin in the 
treatment outcome after the mice being infected with PVL-positive MRSA (Yanagihara 
et al., 2009). They found that following antibiotics administration for 1 day, there were 
no significant differences in the number of bacteria in the lungs between the control, 
linezolid and vancomycin groups (Yanagihara et al., 2009). However, after antibiotics 
administration for 3 days, the number of viable bacteria for the linezolid and vancomycin 
groups were lower than that for the control group and linezolid significantly reduced the 
colony-forming unit/lung compared with the control and the vancomycin groups 
(Yanagihara et al., 2009). Histological examination of the lung specimens showed that 
there were fewer abscesses and less inflammation for the linezolid group than the 
vancomycin and the control groups (Yanagihara et al., 2009). Cytokine analysis also 
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showed that for both the linezolid and vancomycin groups there were significantly lower 
concentration of pro-inflammatory cytokines (TNFa, MIP-2 and IL-ip) than the control 
group, with all of the cytokine concentration of the linezolid group being lower than the 
vancomycin group (Yanagihara et al., 2009). Also, the survival rate at day 7 post-
infection was higher for the linezolid group (100%) than the vancomycin group (50%) 
and the control group (0%) (Yanagihara et al., 2009). These findings support that 
linezolid significantly reduced the number of viable bacteria and the level of 
inflammation in the lung and improved the survival rate of infected mice at day 7 post-
inoculation and linezolid showed a better efficacy than vancomycin in the treatment 
against PVL-positive MRSA infection (Yanagihara et al” 2009). 
In this present study, the in vivo results do not show a significant difference in the 
treatment outcome between the linezolid and the vancomycin groups. This may be 
�because the mice in this study were sacrificed 24 hours after MRSA infection. However, 
the in vivo results demonstrate that both linezolid and vancomycin do not worsen the 
condition of necrotizing pneumonia since there is no significant difference in the 
mortality rate between the linezolid and vancomycin groups compared with the control 
group. 
4.3 Correlation of effects of subinhibitory antibiotics on the 
expression of mRNA in MRSA in vitro and on MRSA pneumonia 
in a murine model 
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Recently, a novel virulence factor of Staphylococcus aureus called phenol-soluble 
modulins (PSMs) have been identified, which have the cytolytic activity against human 
neutrophils and have been proposed to be the major player in PMNs lysis and pneumonia 
rather than PVL (Wang et al, 2007 and Kongo et al., 2009). Table 3.1 summarizes the 
effects of the seven antibiotics on the PVL and PSMal-4 expression of the CA-MRSA. 
Given that the mortality rate of mice is significantly higher for ciprofloxacin, 
clindamycin and fUsidic acid compared with the control, the in vitro effect of the 
antibiotics on PVL expression alone cannot fully explain this. However, taken into 
account of the PSMal-4 expression, the in vitro and in vivo results can be correlated. 
It was found that in order to produce a significant increase in mortality rate of mice, 
PSMal and PSMa3 expression must be increased by the antibiotics and PSMa2 
expression must be in no difference compared with the control. In the in vivo experiment, 
� t h e mortality rate is the highest for the ciprofloxacin (83%) followed by clindamycin 
(50%) and fusidic acid (33%). From the table 3.1, for ciprofloxacin there were increased 
PSMal and PSMaS expression and no difference in PSMa2 expression at two phases, the 
early stationary (OD 2.1) and the stationary phases (OD2.3). The same expression pattern 
was observed for clindamycin at OD 2.3 and for fusidic acid at OD 1.8 and 2.1. The 
reason for the higher mortality rate for ciprofloxacin than clindamycin may be because 
for ciprofloxacin there was an increase in PVL expression at OD 2.1 and 2.3 while an 
inhibitory effect was observed for clindamycin at OD 2.3. This may suggest that the 
presence of PSMs is more important than PVL in the cause of necrotizing pneumonia. 
Another reason may be because there were two phases having this pattern (increased 
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PSMal and PSMa3 expression and no difference in PSMa2 expression) for ciprofloxacin 
while there was only one phase having this pattern for clindamycin. For fiisidic acid, the 
mortality rate is lower than that of ciprofloxacin and clindamycin. It may be because 
although there were two phases having the same pattern (at OD 1.8 and 2.1) and PVL 
expression was increased at these two phases, the magnitude of the increase in PSMal 
and PSMa3 expressions was much lower compared with that for the ciprofloxacin and 
clindamycin groups (figures 3.4 and 3.6). For levofloxacin and linezolid, the mortality 
rate was no difference compared with the control in the in vivo experiment and these 
groups had an increased PSMa2 expression compared with the control at OD 2.1 and 2.3 
in vitro, although PSMal and PSMa3 expression were increased. It seemed that PSMa2 
may exhibit an inhibitory effect on the cause of pneumonia. 
The result showed that PSMa3 is one of the essential virulence factors that contribute to 
� t h e increased mortality rate and this is compatible with the findings done by the Kongo et 
al. group, who found that PSMa3 enhances PVL-mediated human neutrophil lysis 
(Hongo et al., 2009). There was a synergistic effect between PVL and PSMa3 in human 
PMNs lysis (Hongo et al., 2009). They also found that the lysis induced by PSMa3 was 
more rapid than that caused by PVL and so they proposed PSMa3 acted in a different 
mode in PMNs lysis than PVL did (Hongo et al., 2009). 
From the results subinhibitory concentration of clindamycin and linezolid increased 
PSMa expression in the in vitro experiment and this was consistent with the findings 
done by Joo et al.. They also demonstrated that the agr expression was significantly 
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increased by clindamycin and PSMs expression changed accordingly, suggesting that the 
increase in PSM production under the effect of clindamycin is mediated through agr (Joo 
etal.，2010). 
The contribution of PSMs to the enhanced virulence of CA-MRSA has also been proven 
by another research group (Wang et al., 2007). Virulence of an isogenic CA-MRSA with 
the PSMs gene loci deleted and the wild-type strain was compared in mouse abscess and 
bacteremia models (Wang et al., 2007). They found that the mortality rate of mice 
infected with PSMa deleted strain was significantly decreased compared with those 
infected with wild-type strain in the bacteremia mice model (Wang et al., 2007). The S-
toxin deleted strain also caused a decrease in mortality rate, but at a lesser extent (Wang 
et al., 2007). In addition, the level of inflammatory cytokine TNF-a in blood was also 
reduced in mice infected with the PSMa- and 5-toxin- negative strains 6-toxin (Wang et 
al” 2007). Moreover, the PSMa deleted strain also significantly reduced the ability of the 
strain to cause skin lesions in mice and this effect was not seen in the other PSMs deleted 
strains (Wang et al., 2007). Taken together, PSMa peptides are essential in the virulence 
of CA-MRSA (Wang et al , 2007). 
PSMa peptides, particularly PSMa3, were also reported to have a greater effect on 
neutrophil lysis than the PSMp and 6-toxin (Wang et al., 2007). The PSMP- and S-toxin-
deleted strains did not demonstrate a significant decrease in human neutrophil lysis 
(Wang et al.，2007). 
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PVL and PSMs production were suggested to be control by the agr quorum-sensing 
system，but via two different pathways, the RNAIII-dependent control and the RNAIII-
independent control respectively (Queck et al., 2008). The RNAIII-dependent control is 
mediated by the direct base pairing of the RNAIII to the target gene mRNA or to the 
repressor protein gene rot while the RNAIII-independent control is achieved by the direct 
binding of the AgrA protein to the promoter of the target gene (Queck et al., 2008). In 
this study both of the PVL and PSMs gene expression is modulated by different classes 
of antibiotics and this regulatory effect may be mediated through the agr quorum-sensing 
system since both of them are under the control of this system. 
According to the UK guidelines for the treatment of PVL-associated necrotizing 
pneumonia, a combination of rifampicin, linezolid and clindamycin was 
recommomended as an empirical theraphy (PVL sub-group of the Steering Group on 
Healthcare Associated Infection, 2008). It stated that the purpose of using linezolid was 
to suppress PVL production and rifampicin was used as it can easily penetrate into tissue 
and exhibited synergistic effect with linezolid (PVL sub-group of the Steering Group on 
Healthcare Associated Infection, 2008). In the current study, however, it was found that 
sub-inhibitory concentration of linezolid could increase PVL mRNA expression in vitro 
and mice treated with clindamycin had a significantly higher mortality rate than the 
control group, whereas the effect of rifampicin on PVL production has not been evaluated. 
The results of this study may be taken into consideration when treatment of necrotizing 
pneumonia caused by CA-MRSA is carried out. 
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4.4 Limitations of Study 
In the current study, only one of the representative strains of CA-MRSA in Hong Kong 
has been done due to the limitation of time. For the in vitro experiment, the expression of 
pvl and psmal-4 genes was measured at the RNA level. The protein level of these 
virulence genes was not measured. Since some antibiotics, including linezolid, 
gentamicin, fusidic acid and clindamycin were protein synthesis inhibitors, it may have 
the chance that not all the mRNA will be translated into the proteins. For the in vivo 
experiment, the role of PVL and PSMal-4 in the cause of necrotizing pneumonia in mice 
has not been proven. The harvest time for mice was set at 24hr and some mice were dead 
at the time of harvest. The time when the mice were dead was unknown. Also, the 
histological result would be better if the mice were harvested just before death. 
4.5 Future Work 
In this experiment, only the mortality rate and pneumonia grade of mice were assessed 
and whether the cause of mortality or pneumonia was due to PVL or PSM production 
was unknown. An isogenic PVL- and PSM- knockout strain can be established to 
demonstrate the role of PVL and PSM in necrotizing pneumonia in vivo using a mouse 
model. Secondly, pathway or mechanism that alters the PVL gene expression in the 
presence of different antibiotics can further be elucidated. A microarray study can be 
carried out to investigate the pathway through which these antimicrobials affect the PVL 
gene expression. Also, virulence factors other than PVL, such as PSM, that may be 
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involved in the cause of necrotizing pneumonia can also be further investigated. Other 
CA-MRSA strains such as ST59 or even non-Hong Kong strains and additional 
antibiotics such as rifampicin could be tested. 
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Chapter 5 Conclusions 
According to previous findings, it was found that necrotizing pneumonia caused by PVL 
has a mortality rate of 75% and PVL-expressing strains are frequently associated with 
complications (Diimitrescu et al., 2008). It was also shown that sub-inhibitory 
concentration of P-lactams affects PVL production in S. aureus (Dumitrescu et al., 2008). 
For example, subinhibitory concentration of oxacillin increased PVL protein production 
of S. aureus (Dumitrescu et al., 2008). This suggests that the effect of antibiotics on PVL 
toxin release should be considered when decision of the use of antibiotics for the 
treatment of PVL-positive staphylococcal infection is made (Dumitrescu et al., 2008). 
Moreover, the mortality rate 48hr after admission for patients infected with PVL-positive 
S. aureus has been shown to be much higher than for those infected with PVL-negative 
strain (37% for PVL-positive patients and 6% for PVL-negative patients) (Gillet et al” 
2002). This indicates that the PVL toxin may enhance the mortality rate of staphylococcal 
infection (Gillet et al., 2002). Understanding the drugs that affect its expression will be a 
requisite in the choice of treatment in PVL-producing CA-MRSA infections. The choice 
of antibiotics that minimizes release of PVL may reduce severity of disease and improve 
treatment outcome in CA-MRSA infections. 
The expression of staphylococcal PVL in CA-MRSA (Southwest Pacific clone, ST30, 
spa to 19) prevalent in Hong Kong could be affected by the use of different classes of 
antimicrobials. From the in vitro result, PVL mRNA expression was increased by' all 
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antibiotics, including ciprofloxacin, gentamicin, levofloxacin, vancomycin, fusidic acid 
and linezolid but not clindamycin at different growth phases while PSMal-4 mRNA 
expression was modulated in different ways by different antibiotics. Infected mice treated 
with ciprofloxacin, clindamycin and fusidic acid have a significantly higher mortality rate 
than the control group (without antibiotic treatment). In contrast, there was no difference 
in mortality rate for the mice administered with gentamicin, levofloxacin, vancomycin 
and linezolid compared with the control group. 
Taken together vancomycin, linezolid, gentamicin and levofloxacin but not ciprofloxacin, 
clindamycin and fiisidic acid appeared to produce better outcome and might be preferred 
choices in the treatment of the CA-MRSA strain prevalent in Hong Kong. The drug, 
ciprofloxacin, upregulated mRNA expression of pvl significantly and mechanisms 
influencing the regulations of these virulence factors need to be further elucidated. PVL 
may be one of the virulence factors that contribute to necrotizing pneumonia and be 
modulated by different antibiotics but other factors, such as PSMal and PSMa3 are also 
affected and participate in the pathogenesis of MRSA of pneumonia. 
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Appendix I- Materials and Reagents 
(1) Culture of organism 
Materials and reagents Source 
Blood agar Biogene Technology Limited, UK 
Brain heart infusion broth 
Horse serum 
Incubator (37�C supplemented with 5% HKAE, USA 
CO2) |_ 
(2) Collection of bacterial fraction 
Materials and reagents Source 
Antibiotics Sigma, USA 
vancomycin, linezolid, ciprofloxacin, 
fusidic acid, levofloxacin, gentamicin and 
clindamycin 
RNAprotect Bacteria Reagent Qiagen, USA 
(3) RNA extraction and DNA digestion 
Materials and reagents Source 
RNeasy Mini Kit Qiagen, USA 
lysozyme GE Biosciences, USA 
TURBO DNA-free kit Ambion，USA 
(4) Gel electrophoresis 
Materials and reagents Source 
lOObp marker Promega, USA 
Seakem LE agarose BMA, USA . 
TBE buffer GE Biosciences, USA 
SYBR-Green stain Promega, USA 
Electrophoresis apparatus Bio-Rad, USA 
Bio-Rad Gel Doc 2000 System Bio-Rad, USA 
(5) Reverse transcription for cDNA synthesis 
Materials and reagents Source 
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superscript III Reverse Transcriptase Invitrogen, USA 
random primers (250ng/jil) Invitrogen, USA 
dNTP Mix (lOmM) Applied Biosystems，USA 
Thermocycler Applied Biosystems, USA 
5X First-Strand Buffer Invitrogen, USA 
DTT (0.1 M) Invitrogen, USA 
RNaseOUT Recombinant RNase Inhibitor Invitrogen, USA 
(40 units尔 1) 
(6) Quantitative real-time PCR (qPCR) analysis 
Materials and reagents Source 
ABI Prism 7700 Sequence Detector Applied Biosystems, USA 
Power SYBR Green PCR master Applied Biosystems, USA 
MicroAmp® Optical 96-Well Reaction Applied Biosystems, USA 
Plate Applied Biosystems, USA 
the software Sequence Detection System 
version 1.9.1 
(7) Polymerase chain reactions 
Materials and reagents Source 
Custom primers Invitrogen, USA 
1 OX PCR buffer Applied Biosystems, USA 
MgCl2 (25mM) Applied Biosystems, USA 
dNTP (lOjiM), Applied Biosystems, USA 
Taq polymerase (lunit/p,l) Applied Biosystems, USA 
(8) Cloning reaction and plasmid extraction 
Materials and reagents Source 
TOPO® TA cloning kit Invitrogen, USA 
One Shot® Chemically Competent E, coli Invitrogen, USA 
S.O.C. medium Invitrogen, USA 
LB broth Biogene Technology Limited, UK 
Ml3 forward and reverse primers Invitrogen, USA 
QIAprep Miniprep kit Qiagen, USA 
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Appendix II- Mean and standard deviation of the 
copy number ratio {pvl or psmal-4 copy 
number/2 copy number) 
(1) Mean and standard deviation of PVL copy number ratio 
一 I OD I Mean SD 
Control 03 2.18E-05 2.57E-06 
0.6 2.54E-05 2.07E-06 
1.8 7.09E-05 1.60E-06 
2.1 8.82E-05 8.75E-07 
2.3 1.71E-04 1.70E-05 
Ciprofloxacin 03 2.39E-05 6.84E-06 
0.6 4.33E-05 1.22E-05 
1.8 9.14E-05 2.15E-05 
2.1 1.98E-04 3.96E-05 
2.3 2.32E-04 2.44E-05 
Linezolid 03 1.17E-05 1.27E-06 
0.6 1.53E-05 5.55E-06 
1.8 1.25E-04 7.15E-06 
2.1 1.62E-04 2.09E-05 
2.3 1.61E-04 2.72E-05 
Fusidic acid 03 1.30E-05 2.31E-06 
0.6 1.14E-05 8.62E-07 
1.8 1.04E-04 4.72E-06 
� 2.1 1.50E-04 1.14E-05 
2.3 1.42E-04 3.00E-05 
Gentamicin 03 1.72E-05 9.65E-08 
0.6 1.39E-05 2.09E-06 
1.8 l . lOE-04 6.16E-06 
2.1 1.19E-04 6.33E-0'6 
2.3 2.23E-04 2.74E-05 
Levofloxacin 1.66E-05 3.25E-07 
0.6 1.36E-05 1.67E-06 
1.8 1.07E-04 9.09E-06 
2.1 1.75E-04 1.75E-05 
2.3 2.39E-04 L25E-05 
Vancomycin 03 2.40E-05 2.46E-06 
0.6 1.55E-05 2.19E-06 
1.8 7.32E-05 l.llE-05 
2.1 1.84E-04 L52E-05 
2.3 1.71E-Q4 L80E-05 
Clindamyclin 03 2.39E-05 4.41E-06 
0.6 2.67E-05 5.02E-07 
1.8 6.43E-05 7.77E-06 
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2.1 8.88E-05 1.67E-05 
2.3 9.24E-05 1.43E-05 
(2) Mean and standard deviation ofPSMal copy number ratio 
OD Mean SD 
Control ^ 1.57E-04 l.llE-05 
1.8 2.53E-04 1.42E-05 
2.1 4.54E-04 3.68E-05 
2.3 2.57E-03 2.30E-04 
Ciprofloxacin 0.6 3.07E-04 1.27E-04 
1.8 3.30E-04 9.49E-05 
2.1 1.45E-03 4.32E-04 
2.3 4.64E-03 3.60E-04 
Linezolid 0.6 2.89E-04 4.74E-05 
1.8 6.80E-04 1.74E-04 
2.1 3.20E-03 5.30E-04 
23 9.12E-03 8.55E-04 
Fusidic acid 0 6 1.71E-04 4.33E-05 
1.8 4.29E-04 2.69E-05 
2.1 1.12E-03 3.81E-04 
2.3 2.49E-03 3.11E-04 
Gentamicin 0 6 2.29E-04 3.19E-05 
1.8 5.36E-04 4.91E-05 
2.1 1.71E-03 2.04E-04 
2.3 3.20E-03 5.68E-04 
�Levof loxacin 0.6 4.61E-05 6.41E-06 
1.8 3.56E-04 3.36E-05 
2.1 9.75E-04 5.81E-05 
2.3 3.82E-03 7.05E-04 
Vancomycin 0^6 1.49E-04 4.42E-05-
1.8 2.10E-04 5.15E-05 
2.1 6.53E-04 1.08E-04 
2.3 2.68E-03 4.26E-04 
Clindamyclin 0.6 2.66E-04 5.12E-05 
1.8 4.53E-04 3.22E-05 
2.1 1.45E-03 3.25E-04 
2.3 5.22E-03 6.82E-04 
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(3) Mean and stodard deviation of PSMa2 copy number ratio 
OP Mean 丨 SD 
Control 0.6 1.84E-04 2.67E-05 
1.8 2.78E-04 8.35E-06 
2.1 6.00E-04 1.07E-04 
一二 2.3 3.09E-03 3.70E-04 
Ciprofloxacin 2.83E-04 1.18E-04 
1.8 2.72E-04 7.09E-05 
2.1 8.69E-04 2.23E-04 
2.3 3.37E-03 4.1QE-04 
Linezolid 06 1.59E-04 1.29E-05 
1.8 4.29E-04 2.92E-05 
2.1 1.70E-03 9.59E-05 
2.3 6.78E-03 1.42E-03 
Fusidic acid 0.6 1.26E-04 1.62E-05 
1.8 2.97E-04 1.05E-05 
2.1 5.82E-04 1.48E-04 
2.3 1.53E-03 8.11E-Q5 
Gentamicin 0.6 2.48E-04 l.lOE-04 
1.8 6.81E-04 2.37E-05 
2.1 1.39E-03 7.21E-05 
2.3 3.63E-03 3.60E-04 
Levofloxacin 0.6 7.02E-05 6.87E-06 
1.8 3.31E-04 8.31E-05 
� 2.1 1.45E-03 2.86E-04 
2.3 4.49E-03 3.42E-04 
Vancomycin 06 1.04E-04 3.48E-05 
1.8 1.63E-04 3.80E-05 
2.1 4.87E-04 9.84E-05. 
2.3 2.30E-03 3.73E-04 
Clindamyclin 2 . 6 0 E - 0 4 2 . 6 9 E - 0 5 
1.8 3.73E-04 3.86E-05 
2.1 1.17E-03 1.68E-04 
2.3 3.53E-03 9.85E-04 
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(4) Mean and standard deviation ofPSMa3 copy number ratio 
— I OD Mean SD — 
Control 0.6 1.04E-04 2.32E-05 
1.8 8.51E-05 1.51E-05 
2.1 1.41E-04 6.05E-06 
23 4.98E-04 2.11E-05 
Ciprofloxacin ^ 1.31E-04 3.49E-05 
1.8 1.40E-04 3.38E-05 
2.1 3.52E-04 1.18E-04 
2.3 1.18E-03 1.89E-04 
Linezolid ^ 1.40E-04 1.70E-05 
1.8 2.93E-04 6.71E-05 
2.1 L07E-03 9.33E-05 
23 2.82E-03 1.90E-04 
Fusidic acid 0.6 7.02E-05 1.72E-05 
1.8 1.39E-04 1.68E-05 
2.1 2.62E-04 2.41E-05 
23 6.83E-04 7.66E-05 
Gentamicin 0.6 2.08E-04 1.62E-05 
1.8 2.74E-04 5.65E-05 
2.1 6.03E-04 1.07E-04 
2.3 1.47E-03 5.76E-05 
�Levofloxacin ^ 3.83E-05 6.53E-06 
1.8 1.05E-04 1.94E-05 
2.1 4.17E-04 6.99E-05 
2.3 1.14E-03 9.42E-05 
Vancomycin ^ 1.34E-04 2.62E-05-
1.8 7.49E-05 2.01E-05 
2.1 1.50E-04 3.10E-05 
2.3 6.17E-04 6.38E-05 
Clindamyclin 1.59E-04 2.90E-05 
1.8 1.13E-04 1.79E-05 
2.1 4.50E-04 1.03E-04 
2.3 1.61E-03 3.23E-04 
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(5) Mean and stodard deviation ofPSMa4 copy number ratio 
一 I OD I Mean b 
Control 0.6 6.16E-05 3.19E-06 
1.8 1.05E-05 1.12E-06 
2.1 1.81E-05 2.23E-06 
• 2.3 2.12E-05 7.80E-07 
Ciprofloxacin 0.6 1.34E-05 2.99E-06 
1.8 7.44E-06 1.26E-06 
2.1 4.46E-05 1.05E-05 
2.3 1.05E-04 239E-05 
Linezolid 06 2.06E-05 7.46E-06 
1.8 3.86E-05 5.32E-06 
2.1 1.25E-04 4.66E-05 
2.3 3.67E-04 3.89E-05 
Fusidic acid 0.6 2.49E-05 1.25E-06 
1.8 4.13E-05 4.49E-06 
2.1 7.22E-05 6.64E-06 
2.3 1.62E-04 3.32E-05 
Gentamicin 0.6 6.87E-05 1.59E-05 
1.8 8.36E-05 1.83E-05 
2.1 1.55E-04 3.34E-05 
2.3 3.23E-04 1.59E - 06 
Levofloxacin 0.6 2.11E-05 2.07E-06 
1.8 4.05E-05 7.46E-06 
� 2.1 9.90E-05 2.33E-05 
2.3 3.68E-04 3.43E-05 
Vancomycin 06 l.OlE-04 1.46E-05 
1.8 5.73E-05 7.64E-06 
2.1 7.62E-05 7.56E-06 
2.3 1.82E-04 8.19E-06 
Clindamydin 06 1.05E-04 5.20E-06 
1.8 3.03E-05 7.25E-06 
2.1 7.77E-05 1.93E-06 
2.3 1.86E-04 9.96E-06 
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Appendix III- in vivo experimental data for 
infected control group and seven antibiotic groups 
Control group (infected) (n=42) 
Status Pneumonia of tissue 
(24hr post-infection) grading (24hr post-mfection) 
Lung Liver Spleen 
1 Survived 5A >10 0 0 
2 Survived 5A lO -^lO"^  <10^ 0 
3 Dead 5B >10^ <10^ 0 
4 Survived 5A lO -^lO"^  <10^ <10^ 
5 Dead 5B >10"^  <10^ 0 
6 Survived 5 A >10"^  <10^ <10^ 
7 Survived 5B >10"^  10^-10^ lO -^lO"^  
8 Survived 5A >10^ lO -^lO"^  lO -^lO"^  
9 Survived 5A >10"^  <10^ <10^ 
10 Survived 5A >10^ ^ lO -^lO"^  10 -^10^ 
11 Dead 5B >10^ lO -^lO"^  10 -^10^ 
12 Survived 5A >10^ 10^-10^ <10^ 
13 Dead 5B >10"^  0 0 
14 Survived 5A 1 0 ^ - 0 0 
15 Survived 5A lO -^lO"^  <10^ <10^ 
16 Survived 5 A >10"^  <10^ <10^ 
17 Survived 5B >10^ <10^ <10^ 
� 18 Survived 5A >10"^  10^ -10"^  <10^ 
19 Survived 5A >10^ ^ <10^ <10^ 
20 Survived 5 A >10^ ^ 0 <10^ 
21 Survived 5A MO* <10^ 0 
22 Survived 5A >10^ ^ <10^ <10^ 
23 Survived 5A lO -^lO"^  <10^ <10^ 
24 Survived 5B HO* <10^ 0 
25 Survived 5A lO^-lO'' 0 0 
26 Survived 5A lO -^lO"^  <10^ 0 
27 Survived 5A >10^ ^ lO -^lO"* <10^ 
28 Dead 5B >10^ 10^-10^ <10^ 
29 Survived 5A 10^-10^ <10^ 0 
30 Survived 5A lO -^lO"^  <10^ 0 
31 Survived 5B >10^ 10^-10^ 10 -^10^ 
32 Dead 5B >10^ 10^-10^ 10 -^10^ 
33 Survived 5A >10^ lO -^lO"^  lOMo* 
34 Survived 5A >10"^  <10^ <10^ 
35 Survived 5A >10"^  lO -^lO'^  10 -^10^ 
36 Survived 5A >10"^  lO -^lO"^  lO -^lO"^  
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37 Survived 5A >10"^  lO -^lO"^  lO -^lO'^  
38 Survived 5A >10"^  <10^ <10^ 
39 Survived 5A lO -^lO"^  0 0 
40 Survived 5 A lO -^lO"^  0 0 
41 Dead 5B >10^ lO -^lO"^  10 -^10^ 
^ Survived ^ 10^-10^ <10^ Q 
Ciprofloxacin group (n=18) 
AT ^ Status Pneumonia n ^ m g o ^ j i e 
(24hr post-infection) grading (24hr post-mfection)—— 
^ ， ^ ^ Lung Liver Spleen 
1 Survived 5B >10^ <10^ 0 
2 Dead 5B >10^ lO -^lO"^  lO -^lO"^  
3 Survived 5A >10"^  <10^ <10^ 
4 Dead 5B >10"^  1 0 ^ - < 1 0 ^ 
5 Dead 5B >10"^  <10^ <10^ 
6 Survived 5B >10"^  lO -^lO"^  <iO^ 
7 Dead 5B >10"^  <10^ <10^ 
8 Dead 5B >10"^  <10^ lO -^lO"^  
9 Dead 5B >10^ lOMO* 10 -^10^ 
10 Dead 5B >10"^  10 -^10'^  lO -^lO"^  
11 Dead 5B >10^ 10^-10^ 10 -^10^ 
12 Dead 5B >10^ lO -^lO"^  10^-10^ 
13 Dead 5B MO* lO -^lO"^  <10^ 
14 Dead 5B >10"^  <10^ lO -^lO"^  
� 15 Dead 5B >10^ * lO -^lO"^  lO -^lO"^  
16 Dead 5B >10"^  <10^ <10^ 
17 Dead 5B >10"^  0 <10^ 
18 Dead ^ >10^ <10^ <10^ 
Clindamycin group (n=18) 
� T » . CFU/mg of tissue Tv/r u Status Pneumonia , ,儿 ^ . , ^ � 
(24hr post-infection) grading (24hr posMnfection) _ _ 
� ^ ， fe s Lung Liver Spleen 
1 Dead Jb >10^ 10^-10^ 10^-10^ 
2 Dead 5B >10^ 10^-10^ 10^-10^ 
3 Dead 5B >10^ 10^-10^ <10^ 
4 Dead 5B >10^ ^ ioMO* lO -^lO"^  
5 Dead 5B >10"^  lO -^lO"^  lO -^lO"^  
6 Survived 5B lO -^lO"^  lO -^lO"^  0 
7 Dead 5B >10^ ^ lO -^lO"^  lO -^lO"* 
8 Survived 5 A 10^-10^ lO -^lO"^  lO -^ld"^  
9 Survived 5A 10^-10^ <10^ 0 
10 Dead 5B >10^ lO -^lO"^  <10^ 
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11 Survived 5A >10^ lO -^lO"^  10 -^10^ 
12 Dead 5B 10 -^10^ 0 0 
13 Survived 5A >10^ lO -^lO"^  10 -^10^ 
14 Dead 5B >10^ lO -^lO"^  lO -^lO"^  
15 Survived 5A >10"^  lO -^lO"^  >10"* 
16 Survived 5A >10"^  lO -^lO"^  
17 Survived 5A 10M04 <10^ 0 
18 Survived 5A >10^ <10^ Q 
Fusidic acid group (n=18) 
. Status Pneumonia ‘ ？f f ， 
歸 （ 2 4 h r post-infection) grading (24hr post-mfectiop) 
) ^ ^ Lung Liver Spleen 
1 Survived 5A >10^ <10^ 0 
2 Dead 5B >10^ 10 -^10^ 10 -^10^ 
3 Survived 5A 10 -^10^ <10^ <10^ 
4 Dead 5B >10^ 10^-10^ 10 -^10^ 
5 Survived 5 A >10"^  <10^ <10^ 
6 Survived 5A >10"^  1 0 ^ - 1 
7 Dead 5A >10^ lO -^lO"^  <10^ 
8 Survived 5A >10'' 0 <10^ 
9 Survived 5A MO* lO -^lO"^  <10^ 
10 Dead 5A >10^ <10^ 0 
11 Survived 5A >10"^  <10^ <10^ 
12 Dead 5B >10^ ^ lO -^lO"^  10 -^10^ 
� 13 Survived 5A lO -^lO"^  <10^ <10^ 
14 Survived 5A lO -^lO"^  lO -^lO"^  1 
15 Dead 5B >10^ lO -^lO"^  10 -^10^ 
16 Survived 5 A >10"^  <10^ 0 
17 Dead 5B >10^ 10^-10^ lO -^lO"^  
18 Survived SK 10 -^10^ <10^ <10^ 
Linezolid group (n=18) 
Status Pneumonia j J f U / m g of tissue 
(24hr post-infection) grading (24hr post-mfection) 
^ Lung Liver Spleen 
1 Survived 5A >10 <10^ <io^ 
2 Dead 5B 10 -^10^ <10^ <10^ 
3 Survived 5B >10"* 0 0 
4 Survived 5 A >10)4 0 0 
5 Survived 5B >10"^  <10^ <10^ 
6 Survived 5B >10"^  1 0 ^ - < 1 0 ^ -
7 Survived 5A >10"^  <10^ <io^ 
8 Dead 5B >10^ 10^-10^ <10^ 
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9 Survived 5B >10"* <10^ <io^ 
10 Survived 5 A >10"^  <10^ <io^ 
11 Survived 5 A >10"^  <10^ 0 
12 Survived 5B >10"^  <10^ 
13 Survived 5 A >10^ * <10^ <10^ 
14 Dead 5B >10"^  10 -^10^ 10^ -10"^  
15 Survived 5B >10"^  <10^ <io^ 
16 Survived 5A >10"* <10^ 0 
17 Survived 5B >10"^  <10^ <io^ 
18 Dead 5B >10^ <10^ <10^ 
Gentamicin group (n=18) 
Status Pneumonia 加 g ‘ � [，難 
(24hr post-infection) grading (24hr post-infection) 
Lung Liver Spleen 
1 Survived 5A >10 0 0 
2 Survived 5B lO -^lO"^  <10^ 0 
3 Survived 5 A >10"^  <10^ <io^ 
4 Dead 5B >10"^  0 0 
5 Survived 5B lO -^lO"^  lO^-lO'' lO -^lO"^  
6 Survived 5 A >10"^  <10^ 0 
7 Survived 5B >10"^  <10^ <io^ 
8 Survived 5A >10^ ^ 10^ -10"^  <10^ 
9 Survived 5A >10"^  lO -^lO"^  <10^ 
10 Survived 5A 10 -^10^ <10^ <10^ 
� 11 Dead 5B >10"^  0 0 
12 Survived 5A >10^ 10 -^10^ <10^ 
13 Survived 5A lO -^lO"^  <10^ <10^ 
14 Dead 5B >10^ <10^ 0 
15 Survived 5A >10^ 1 0 ^ - < 1 0 ^ 
16 Dead 5B 10 -^10^ <10^ 0 
17 Survived 5 A lO -^lO'^  <10^ 0 
1 8 Survived 5A <10^ 0 Q 
Vancomycin group (n=18) 
Mi沖“ Status Pneumonia ^ ^ ^ m g of tissue 
歸 ( 2 4 h r post-infection) grading ——(24hr post-infection) 
) ^ ^ Lung Liver Spleen 
1 Survived >10 <10^ 0 
2 Survived 5A lOMO^ <10^ <10^ 
3 Dead 5B >10"^  <10^ <10^ 
4 Survived 5 A >10'^  0 10 -^10'^  
5 Survived 5 A >10"^  <10^ lO -^lO"^  
6 Survived 5B >10'^  <10^ lO^-lO'' 
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7 Survived 5A 10 -^10^ <10^ <10^ 
8 Dead 5B >10'' <10^ <10^ 
9 Survived 5A >10^ ^ 10 -^10'^  <10^ 
10 Dead 5B 10 -^10^ 0 0 
11 Survived 5 A >10"^  <10^ <10^ 
12 Survived 5B >10"^  0 <10^ 
13 Survived 5A >10"^  <10^ 0 
14 Survived 5A >10^ ^ <10^ 0 
15 Survived 5B >10"^  <10^ lO -^lO"^  
16 Survived 5A >10"^  <10^ lO -^lO"^  
17 Dead 5B >10"^  <10^ <10^ 
n Survived ^ >10^ 0 Q 
Levofloxacin group (n=18) 
A/r. ji Status Pneumonia 弓 of tissue 
(24hr post-infection) grading (24hr post-mfectioii) _ _ 
^ ^ ) s " s Lung Liver Spleen 
T" Survived 5B > W lOMO* l^MO* 
2 Survived 5A lO -^lO"^  0 0 
3 Dead 5B >10,000 10 -^10^ 10 -^10^ 
4 Survived 5A lO -^lO"^  <10^ <10^ 
5 Survived 5B 10 -^10^ 0 0 
6 Survived 5A 10 -^10'^  0 0 
7 Survived 5B >10"^  <10^ lOMO* 
8 Survived 5A >10^ lO -^lO"^  lO -^lO* 
� 9 Survived 5A >10"^  10^-10^ 10 -^10^ 
� 10 Survived 5A 10 -^10^ 10^-10^ 10 -^10^ 
11 Survived 5B lO -^lO"^  <10^ 0 
12 Survived 5B 10 -^10^ <10^ 0 
13 Survived 5A lO -^lO"^  <10^ <10^ 
14 Survived 5A >10- <10^ 0 
15 Dead 5B >10^ lO -^lO"^  lO -^lO'^  
16 Dead 5B >10"^  lO -^lO"^  lO -^lO"^  
17 Dead 5B lO -^lO"^  <10^ 0 
1 8 Survived ^ 10 -^10^ Q • Q 
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